Control system for a particle accelerator

Description

TECHNICAL FIELD

This disclosure relates generally to a control system for a particle accelerator.

BACKGROUND

Particle therapy systems use a particle accelerator to generate a particle beam for treating afflictions, such as tumors. A control system manages the behavior of the particle accelerator to ensure that it operates as desired.

SUMMARY

An example particle therapy system may include a particle accelerator to output a particle beam, where the particle accelerator includes: a particle source to provide pulses of ionized plasma to a cavity, where each pulse of the particle source has a pulse width corresponding to a duration of operation of the particle source to produce the corresponding pulse, and where the particle beam is based on the pulses of ionized plasma; and a modulator wheel having different thicknesses, where each thickness extends across a different circumferential length of the modulator wheel, and where the modulator wheel is arranged to receive a precursor to the particle beam and is configured to create a spread-out Bragg peak for the particle beam. The example particle therapy system also includes one or more first input/output (I/O) modules operable at a first speed, where the one or more first I/O modules are configured to send machine instructions to one or more motor controllers, at least one of which is for controlling the modulator wheel; and one or more second I/O modules operable at a second speed that is greater than the first speed, at least one of which is configured to send machine instructions to the particle source so that pulse widths of the particle source vary with rotational positions of the modulator wheel. The example particle therapy system may also include one or more of the following features:

The example particle therapy system may include: a therapy control computer programmed to receive prescription information from a hospital, to translate the prescription information to machine information, and to send treatment records to the hospital; and a master control computer having a real-time operating system, where the master control computer is programmed to receive machine information from the therapy control computer, to translate the machine information into machine instructions, and to send the machine instructions to one or more of the first I/O modules and the second I/O modules.

The example particle therapy system may include an optical fiber over which is monitored a rotational speed and position of the modulator wheel. A speed of the first I/O modules may be on the order of milliseconds and a speed of the second I/O modules may be on the order of one or more hundreds of nanoseconds.

The first I/O modules may be programmable logic controllers (PLC). At least one of the PLCs may be programmed to send machine instructions to motor controllers for controlling a field shaping wheel system for shaping the particle beam prior to output. At least one of the PLCs may be programmed to send machine instructions to a motor controller for controlling a scattering system for collimating the particle beam prior to output.

The example particle therapy system may include a radio frequency (RF) system to sweep RF frequencies through the cavity to extract particles from a plasma column produced by the particle source, where the RF system includes a rotating capacitor. At least one of the PLCs may be programmed to send machine instructions to a motor controller that controls the rotating capacitor. Two or more of the PLCs may be configured to communicate with one another.

The example particle therapy system may include a rotatable gantry on which the particle accelerator is mounted. At least one of the PLCs may be programmed to send machine instructions to a motor controller that controls the rotatable gantry.

The second I/O modules may be field-programmable gate arrays (FPGA). The example particle therapy system may include a circuit board including a microprocessor. At least one of the FPGAs may be on the circuit board and in communication with the microprocessor. The microprocessor may be programmed to communicate with a control computer.

The example particle therapy system may include a radio frequency (RF) system to sweep RF frequencies through the cavity to extract particles from a plasma column produced by the particle source. At least one of the FPGAs may be an RF control module. The RF control module may be configured to receive information about a rotation of the modulator wheel and, based thereon, to coordinate operational aspects of the particle source and the RF system. Coordinating operational aspects of the particle source and the RF system may include turning the particle source on or off based on a rotational position of the modulator wheel, and turning the RF system on or off based on a rotational position of the modulator wheel. The RF control module may be configured to send machine instruction to the particle source to turn-on when an RF voltage is at a certain frequency and to turn-off when the RF voltage is at a certain frequency. Coordinating operational aspects of the particle source may include specifying pulse widths during turn-on times of the particle source.

An example particle therapy system may include a particle accelerator to output a particle beam included of pulses and a depth modulator that is in a path of the particle beam. The depth modulator has a variable thickness and is movable so that the particle beam impacts different thicknesses of the depth modulator at different times. The particle therapy system is configured to control numbers of pulses that impact the different thicknesses of the depth modulator. The example particle therapy system may include one or more of the following features, either alone or in combination.

Movement of the depth modulator may be controllable so that different numbers of pulses impact at least two different thicknesses of the depth modulator. The particle therapy system may include a control system to provide control signals and a motor to control movement of the depth modulator in response to the control signals, where the movement is rotation that is controllable by the control signals.

Output of pulses from the accelerator may be controlled so that different numbers of pulses impact at least two different thicknesses of the depth modulator. The particle accelerator may include a particle source configured to generate a plasma stream from which the pulses are extracted, where the plasma stream is generated in response to voltage applied to ionized gas, and the voltage is controllable to turn the particle source on and off to control the number of pulses that impact the at least two different thicknesses. The particle accelerator may include a particle source configured to generate a plasma stream from which the pulses are extracted; and a radio frequency (RF) source to sweep frequencies and thereby extract one or more pulses from the plasma stream at each frequency sweep. The RF source may be controllable to control numbers of pulses that impact different thicknesses of the depth modulator. The RF source may be controllable to skip one or more frequency sweeps. The particle therapy system may be configured by including one or more structures to deflect pulses so as to control numbers of pulses that impact different thicknesses of the depth modulator.

An example particle therapy system may include a particle accelerator to output a particle beam, where the accelerator includes: a particle source to provide pulses of ionized plasma to a cavity, where each pulse of the particle source has a pulse width corresponding to a duration of operation of the particle source to produce the corresponding pulse, and where the particle beam is based on the pulses of ionized plasma; and a modulator wheel having different thicknesses, where each thickness extends across a different circumferential length of the modulator wheel, and where the modulator wheel is arranged to receive a precursor to the particle beam and is configured to create a spread-out Bragg peak for the particle beam. The particle therapy system may be configured so that pulse widths of the particle source vary with rotational positions of the modulator wheel.

Two or more of the features described in this disclosure, including those described in this summary section, may be combined to form implementations not specifically described herein.

Control of the various systems described herein, or portions thereof, may be implemented via a computer program product that includes instructions that are stored on one or more non-transitory machine-readable storage media, and that are executable on one or more processing devices. The systems described herein, or portions thereof, may be implemented as an apparatus, method, or electronic system that may include one or more processing devices and memory to store executable instructions to implement control of the stated functions.

The details of one or more implementations are set forth in the accompanying drawings and the description below. Other features, objects, and advantages will be apparent from the description and drawings, and from the claims.

DESCRIPTION OF THE DRAWINGS

FIG. 1 is a perspective view of an example particle therapy system.

FIG. 2 is an exploded perspective view of components of an example synchrocyclotron.

FIGS. 3, 4, and 5 are cross-sectional views of an example synchrocyclotron.

FIG. 6 is a perspective view of an example synchrocyclotron.

FIG. 7 is a cross-sectional view of a portion of an example reverse bobbin and windings.

FIG. 8 is a cross-sectional view of an example cable-in-channel composite conductor.

FIG. 9 is a cross-sectional view of an example particle source.

FIG. 10 is a perspective view of an example dee plate and a dummy dee.

FIG. 11 is a perspective view of an example vault.

FIG. 12 is a perspective view of an example treatment room with a vault.

FIG. 13 shows a patient positioned next to a particle accelerator.

FIG. 14 shows a patient positioned within an example inner gantry in a treatment room.

FIG. 15 is a block diagram showing an example of a control system for a particle accelerator.

FIG. 16 shows an example field shaping wheel system.

FIG. 17 is a side view showing a beam path that includes an example modulator wheel and an example scatterer.

FIG. 18 is a graph showing various Bragg peaks and the cumulative effect that produces a spread-out Bragg peak.

FIG. 19 is a side view of an example modulator wheel for producing Bragg peaks at different depths and intensity levels.

FIG. 20 is a top view of the modulator wheel of FIG. 19.

FIG. 21 is a graph showing a frequency sweep and a particle source pulse width output during a period of the frequency sweep.

FIG. 22 is a graph showing spread-out Bragg peaks at different depths within a patient.

FIG. 23 is a graph showing particle source pulse width relative to the angle of the modulation wheel for the spread-out Bragg peaks of FIG. 22.

Like reference symbols in the various drawings indicate like elements.

DETAILED DESCRIPTION
Overview

Described herein is an example of a control system for an example particle accelerator for use in a system, such as a proton or ion therapy system. The example particle therapy system includes a particle accelerator—in this example, a synchrocyclotron—mounted on a gantry. The gantry enables the particle accelerator to be rotated around a patient position, as explained in more detail below. In some implementations, the gantry is steel and has two legs mounted for rotation on two respective bearings that lie on opposite sides of a patient. The particle accelerator is supported by a steel truss that is long enough to span a treatment area in which the patient lies and that is attached stably at both ends to the rotating legs of the gantry. As a result of rotation of the gantry around the patient, the particle accelerator also rotates.

In an example implementation, the particle accelerator (e.g., the synchrocyclotron) includes a cryostat that holds a superconducting coil for conducting a current that generates a magnetic field (B). In this example, the cryostat uses liquid helium (He) to maintain the coil at superconducting temperatures, e.g., 4° Kelvin (K). Magnetic yokes are adjacent (e.g., around) the cryostat, and define a cavity in which particles are accelerated. The cryostat is attached to the magnetic yokes through straps or the like.

In this example implementation, the particle accelerator includes a particle source (e.g., a Penning Ion Gauge—PIG source) to provide a plasma column to the cavity. Hydrogen gas is ionized to produce the plasma column. A voltage source provides a radio frequency (RF) voltage to the cavity to accelerate particles from the plasma column. As noted, in this example, the particle accelerator is a synchrocyclotron. Accordingly, the RF voltage is swept across a range of frequencies to account for relativistic effects on the particles (e.g., increasing particle mass) when extracting particles from the column. The magnetic field produced by the coil causes particles accelerated from the plasma column to accelerate orbitally within the cavity. A ferromagnetic arrangement (e.g., a magnetic regenerator) is positioned in the cavity to adjust the existing magnetic field inside the cavity to thereby change locations of successive orbits of the particles accelerated from the plasma column so that, eventually, the particles output to an extraction channel that passes through the yokes. The extraction channel receives particles accelerated from the plasma column and outputs the received particles from the cavity. Elements both inside and outside the extraction channel shape and focus the particle beam for application.

A control system can control the behavior of the particle accelerator. In operation, a particle beam from the particle accelerator is applied to a patient in accordance with a particular treatment plan. A prescription defines operational characteristics of the particle therapy system that are used to implement the treatment plan. Although a prescription may specify any number of operational characteristics appropriate to a particular particle therapy system, in an implementation, the prescription specifies one or more of the following: particle dose, particle dose rate, patient position (as defined by a “couch” on which the patient lies), patient couch rotational angle, gantry rotational angle, beam field size, beam depth, an extent of the beam depth, a configuration of an aperture used to limit the area of the particle beam, and a configuration of a range compensating bolus (or, simply, “bolus”) used to customize the penetration depth of the particle beam.

The control system can include a Therapy Control Computer (TCC) that includes a user interface. In an example, the TCC is programmed to receive prescriptions from a hospital and to send treatment records to the hospital. The TCC can also translate the prescription into machine instructions, including, but not limited to, commands, parameters, and/or other machine-usable information.

The TCC can send the translated machine instructions to a Master Control Computer (MCC). The MCC can include a real-time operating system to execute commands at exact times in an exact order. In an example, the MCC is programmed to send machine instructions to slow and fast input/output modules.

In an example implementation, the slow I/O modules are used to send instructions to motor controllers. The motor controllers may control any movable component of the particle accelerator (e.g., field shaping wheels, scattering foils, a rotating capacitor, a depth modulator wheel, the gantry, etc.).

In an example implementation, the fast I/O modules are used for more time sensitive control. For example, it could be appropriate to use the fast I/O module to control an RF voltage source and/or a particle source (because it can be important for one to be turned at exact times relative to the other). The fast I/O modules can also be used to receive data that samples the position of the modulator wheel (because a very high sampling rate may be appropriate).

The slow and fast I/O modules use the machine instructions to configure the particle therapy system so that it has operational characteristics appropriate for the treatment plan. The particle therapy system is configurable on a case-by-case basis.

The techniques described herein for controlling the particle therapy system are not limited to use with a particular particle therapy system, but rather may be used in any appropriate particle therapy system. The foregoing techniques also may be used in other appropriate medical treatment or diagnostic systems.

An example of a particle therapy system in which the foregoing techniques may be used is provided below.

EXAMPLE PARTICLE THERAPY SYSTEM

Referring to FIG. 1, a charged particle radiation therapy system 500 includes a beam-producing particle accelerator 502 having a weight and size small enough to permit it to be mounted on a rotating gantry 504 with its output directed straight (that is, essentially directly) from the accelerator housing toward a patient 506.

In some implementations, the steel gantry has two legs 508, 510 mounted for rotation on two respective bearings 512, 514 that lie on opposite sides of the patient. The accelerator is supported by a steel truss 516 that is long enough to span a treatment area 518 in which the patient lies (e.g., twice as long as a tall person, to permit the person to be rotated fully within the space with any desired target area of the patient remaining in the line of the beam) and is attached stably at both ends to the rotating legs of the gantry.

In some examples, the rotation of the gantry is limited to a range 520 of less than 360 degrees, e.g., about 180 degrees, to permit a floor 522 to extend from a wall of the vault 524 that houses the therapy system into the patient treatment area. The limited rotation range of the gantry also reduces the required thickness of some of the walls, which provide radiation shielding of people outside the treatment area. A range of 180 degrees of gantry rotation is enough to cover all treatment approach angles, but providing a larger range of travel can be useful. For example the range of rotation may be between 180 and 330 degrees and still provide clearance for the therapy floor space.

The horizontal rotational axis 532 of the gantry is located nominally one meter above the floor where the patient and therapist interact with the therapy system. This floor is positioned about 3 meters above the bottom floor of the therapy system shielded vault. The accelerator can swing under the raised floor for delivery of treatment beams from below the rotational axis. The patient couch moves and rotates in a substantially horizontal plane parallel to the rotational axis of the gantry. The couch can rotate through a range 534 of about 270 degrees in the horizontal plane with this configuration. This combination of gantry and patient rotational ranges and degrees of freedom allow the therapist to select virtually any approach angle for the beam. If needed, the patient can be placed on the couch in the opposite orientation and then all possible angles can be used.

In some implementations, the accelerator uses a synchrocyclotron configuration having a very high magnetic field superconducting electromagnetic structure. Because the bend radius of a charged particle of a given kinetic energy is reduced in direct proportion to an increase in the magnetic field applied to it, the very high magnetic field superconducting magnetic structure permits the accelerator to be made smaller and lighter. The synchrocyclotron uses a magnetic field that is uniform in rotation angle and falls off in strength with increasing radius. Such a field shape can be achieved regardless of the magnitude of the magnetic field, so in theory there is no upper limit to the magnetic field strength (and therefore the resulting particle energy at a fixed radius) that can be used in a synchrocyclotron.

Superconducting materials lose their superconducting properties in the presence of very high magnetic fields. High performance superconducting wire windings are used to allow very high magnetic fields to be achieved. Superconducting materials typically need to be cooled to low temperatures for their superconducting properties to be realized. In some examples described here, cryo-coolers are used to bring the superconducting coil windings to temperatures near absolute zero. Using cryo-coolers can reduce complexity and cost.

The synchrocyclotron is supported on the gantry so that the beam is generated directly in line with the patient. The gantry permits rotation of the cyclotron about a horizontal rotational axis that contains a point (isocenter 540) within, or near, the patient. The split truss that is parallel to the rotational axis, supports the cyclotron on both sides.

Because the rotational range of the gantry is limited, a patient support area can be accommodated in a wide area around the isocenter. Because the floor can be extended broadly around the isocenter, a patient support table can be positioned to move relative to and to rotate about a vertical axis 542 through the isocenter so that, by a combination of gantry rotation and table motion and rotation, any angle of beam direction into any part of the patient can be achieved. The two gantry arms are separated by more than twice the height of a tall patient, allowing the couch with patient to rotate and translate in a horizontal plane above the raised floor.

Limiting the gantry rotation angle allows for a reduction in the thickness of at least one of the walls surrounding the treatment room. Thick walls, typically constructed of concrete, provide radiation protection to individuals outside the treatment room. A wall downstream of a stopping proton beam may be about twice as thick as a wall at the opposite end of the room to provide an equivalent level of protection. Limiting the range of gantry rotation enables the treatment room to be sited below earth grade on three sides, while allowing an occupied area adjacent to the thinnest wall reducing the cost of constructing the treatment room.

In the example implementation shown in FIG. 1, the superconducting synchrocyclotron 502 operates with a peak magnetic field in a pole gap of the synchrocyclotron of 8.8 Tesla. The synchrocyclotron produces a beam of protons having an energy of 250 MeV. In other implementations the field strength could be in the range of 6 to 20 Tesla or 4 to 20 Tesla and the proton energy could be in the range of 150 to 300 MeV

The radiation therapy system described in this example is used for proton radiation therapy, but the same principles and details can be applied in analogous systems for use in heavy ion (ion) treatment systems.

As shown in FIGS. 2, 3, 4, 5, and 6, an example synchrocyclotron 10 (e.g., 502 in FIG. 1) includes a magnet system 12 that contains an particle source 90, a radiofrequency drive system 91, and a beam extraction system 38. The magnetic field established by the magnet system has a shape appropriate to maintain focus of a contained proton beam using a combination of a split pair of annular superconducting coils 40, 42 and a pair of shaped ferromagnetic (e.g., low carbon steel) pole faces 44, 46.

The two superconducting magnet coils are centered on a common axis 47 and are spaced apart along the axis. As shown in FIGS. 7 and 8, the coils are formed by of Nb₃Sn-based superconducting 0.8 mm diameter strands 48 (that initially comprise a niobium-tin core surrounded by a copper sheath) deployed in a twisted cable-in-channel conductor geometry. After seven individual strands are cabled together, they are heated to cause a reaction that forms the final (brittle) superconducting material of the wire. After the material has been reacted, the wires are soldered into the copper channel (outer dimensions 3.18×2.54 mm and inner dimensions 2.08×2.08 mm) and covered with insulation 52 (in this example, a woven fiberglass material). The copper channel containing the wires 53 is then wound in a coil having a rectangular cross-section of 8.55 cm×19.02 cm, having 26 layers and 49 turns per layer. The wound coil is then vacuum impregnated with an epoxy compound. The finished coils are mounted on an annular stainless steel reverse bobbin 56. Heater blankets 55 are placed at intervals in the layers of the windings to protect the assembly in the event of a magnet quench.

The entire coil can then be covered with copper sheets to provide thermal conductivity and mechanical stability and then contained in an additional layer of epoxy. The precompression of the coil can be provided by heating the stainless steel reverse bobbin and fitting the coils within the reverse bobbin. The reverse bobbin inner diameter is chosen so that when the entire mass is cooled to 4 K, the reverse bobbin stays in contact with the coil and provides some compression. Heating the stainless steel reverse bobbin to approximately 50 degrees C. and fitting coils at a temperature of 100 degrees Kelvin can achieve this.

The geometry of the coil is maintained by mounting the coils in a reverse rectangular bobbin 56 to exert a restorative force 60 that works against the distorting force produced when the coils are energized. As shown in FIG. 5, the coil position is maintained relative to the magnet yoke and cryostat using a set of warm-to-cold support straps 402, 404, 406. Supporting the cold mass with thin straps reduces the heat leakage imparted to the cold mass by the rigid support system. The straps are arranged to withstand the varying gravitational force on the coil as the magnet rotates on board the gantry. They withstand the combined effects of gravity and the large de-centering force realized by the coil when it is perturbed from a perfectly symmetric position relative to the magnet yoke. Additionally the links act to reduce dynamic forces imparted on the coil as the gantry accelerates and decelerates when its position is changed. Each warm-to-cold support includes one S2 fiberglass link and one carbon fiber link. The carbon fiber link is supported across pins between the warm yoke and an intermediate temperature (50-70 K), and the S2 fiberglass link 408 is supported across the intermediate temperature pin and a pin attached to the cold mass. Each link is 5 cm long (pin center to pin center) and is 17 mm wide. The link thickness is 9 mm. Each pin is made of high strength stainless steel and is 40 mm in diameter.

Referring to FIG. 3, the field strength profile as a function of radius is determined largely by choice of coil geometry and pole face shape; the pole faces 44, 46 of the permeable yoke material can be contoured to fine tune the shape of the magnetic field to ensure that the particle beam remains focused during acceleration.

The superconducting coils are maintained at temperatures near absolute zero (e.g., about 4 degrees Kelvin) by enclosing the coil assembly (the coils and the bobbin) inside an evacuated annular aluminum or stainless steel cryostatic chamber 70 that provides a free space around the coil structure, except at a limited set of support points 71, 73. In an alternate version (FIG. 4) the outer wall of the cryostat may be made of low carbon steel to provide an additional return flux path for the magnetic field.

In some implementations, the temperature near absolute zero is achieved and maintained using one single-stage Gifford-McMahon cryo-cooler and three two-stage Gifford McMahon cryo-coolers. Each two stage cryo-cooler has a second stage cold end attached to a condenser that recondenses Helium vapor into liquid Helium. The cryo-cooler heads are supplied with compressed Helium from a compressor. The single-stage Gifford-McMahon cryo-cooler is arranged to cool high temperature (e.g., 50-70 degrees Kelvin) leads that supply current to the superconducting windings.

In some implementations, the temperature near absolute zero is achieved and maintained using two Gifford-McMahon cryo-coolers 72, 74 that are arranged at different positions on the coil assembly. Each cryo-cooler has a cold end 76 in contact with the coil assembly. The cryo-cooler heads 78 are supplied with compressed Helium from a compressor 80. Two other Gifford-McMahon cryo-coolers 77, 79 are arranged to cool high temperature (e.g., 60-80 degrees Kelvin) leads that supply current to the superconducting windings.

The coil assembly and cryostatic chambers are mounted within and fully enclosed by two halves 81, 83 of a pillbox-shaped magnet yoke 82. In this example, the inner diameter of the coil assembly is about 74.6 cm. The iron yoke 82 provides a path for the return magnetic field flux 84 and magnetically shields the volume 86 between the pole faces 44, 46 to prevent external magnetic influences from perturbing the shape of the magnetic field within that volume. The yoke also serves to decrease the stray magnetic field in the vicinity of the accelerator.

As shown in FIGS. 3 and 9, the synchrocyclotron includes a particle source 90 of a Penning ion gauge geometry located near the geometric center 92 of the magnet structure 82. The particle source may be as described below, or the particle source may be of the type described in U.S. patent application Ser. No. 11/948,662 incorporated herein by reference.

Particle source 90 is fed from a supply 99 of hydrogen through a gas line 101 and tube 194 that delivers gaseous hydrogen. Electric cables 94 carry an electric current from a current source 95 to stimulate electron discharge from cathodes 192, 190 that are aligned with the magnetic field, 200.

In some implementations, the gas in gas tube 101 may include a mixture of hydrogen and one or more other gases. For example, the mixture may contain hydrogen and one or more of the noble gases, e.g., helium, neon, argon, krypton, xenon and/or radon (although the mixture is not limited to use with the noble gases). In some implementations, the mixture may be a mixture of hydrogen and helium. For example, the mixture may contain about 75% or more of hydrogen and about 25% or less of helium (with possible trace gases included). In another example, the mixture may contain about 90% or more of hydrogen and about 10% or less of helium (with possible trace gases included). In examples, the hydrogen/helium mixture may be any of the following: >95%/<5%, >90%/<10%, >85%/<15%, >80%/<20%, >75%/<20%, and so forth.

Possible advantages of using a noble (or other) gas in combination with hydrogen in the particle source may include: increased beam intensity, increased cathode longevity, and increased consistency of beam output.

In this example, the discharged electrons ionize the gas exiting through a small hole from tube 194 to create a supply of positive ions (protons) for acceleration by one semicircular (dee-shaped) radio-frequency plate 100 that spans half of the space enclosed by the magnet structure and one dummy dee plate 102. In the case of an interrupted particle source (an example of which is described in U.S. patent application Ser. No. 11/948,662), all (or a substantial part) of the tube containing plasma is removed at the acceleration region, thereby allowing ions to be more rapidly accelerated in a relatively high magnetic field.

As shown in FIG. 10, the dee plate 100 is a hollow metal structure that has two semicircular surfaces 103, 105 that enclose a space 107 in which the protons are accelerated during half of their rotation around the space enclosed by the magnet structure. A duct 109 opening into the space 107 extends through the yoke to an external location from which a vacuum pump 111 can be attached to evacuate the space 107 and the rest of the space within a vacuum chamber 119 in which the acceleration takes place. The dummy dee 102 comprises a rectangular metal ring that is spaced near to the exposed rim of the dee plate. The dummy dee is grounded to the vacuum chamber and magnet yoke. The dee plate 100 is driven by a radio-frequency signal that is applied at the end of a radio-frequency transmission line to impart an electric field in the space 107. The radio frequency electric field is made to vary in time as the accelerated particle beam increases in distance from the geometric center. The radio frequency electric field may be controlled in the manner described in U.S. patent application Ser. No. 11/948,359, entitled “Matching A Resonant Frequency Of A Resonant Cavity To A Frequency Of An Input Voltage”, the contents of which are incorporated herein by reference.

For the beam emerging from the centrally located particle source to clear the particle source structure as it begins to spiral outward, a large voltage difference is required across the radio frequency plates. 20,000 Volts is applied across the radio frequency plates. In some versions from 8,000 to 20,000 Volts may be applied across the radio frequency plates. To reduce the power required to drive this large voltage, the magnet structure is arranged to reduce the capacitance between the radio frequency plates and ground. This is done by forming holes with sufficient clearance from the radio frequency structures through the outer yoke and the cryostat housing and making sufficient space between the magnet pole faces.

The high voltage alternating potential that drives the dee plate has a frequency that is swept downward during the accelerating cycle to account for the increasing relativistic mass of the protons and the decreasing magnetic field. The dummy dee does not require a hollow semi-cylindrical structure as it is at ground potential along with the vacuum chamber walls. Other plate arrangements could be used such as more than one pair of accelerating electrodes driven with different electrical phases or multiples of the fundamental frequency. The RF structure can be tuned to keep the Q high during the required frequency sweep by using, for example, a rotating capacitor having intermeshing rotating and stationary blades. During each meshing of the blades, the capacitance increases, thus lowering the resonant frequency of the RF structure. The blades can be shaped to create a precise frequency sweep required. A drive motor for the rotating condenser can be phase locked to the RF generator for precise control. One bunch of particles is accelerated during each meshing of the blades of the rotating condenser.

The vacuum chamber 119 in which the acceleration occurs is a generally cylindrical container that is thinner in the center and thicker at the rim. The vacuum chamber encloses the RF plates and the particle source and is evacuated by the vacuum pump 111. Maintaining a high vacuum insures that accelerating ions are not lost to collisions with gas molecules and enables the RF voltage to be kept at a higher level without arcing to ground.

Protons traverse a generally spiral orbital path beginning at the particle source. In half of each loop of the spiral path, the protons gain energy as they pass through the RF electric field in space 107. As the ions gain energy, the radius of the central orbit of each successive loop of their spiral path is larger than the prior loop until the loop radius reaches the maximum radius of the pole face. At that location a magnetic and electric field perturbation directs ions into an area where the magnetic field rapidly decreases, and the ions depart the area of the high magnetic field and are directed through an evacuated tube 38, referred to herein as the extraction channel, to exit the yoke of the cyclotron. A magnetic regenerator may be used to change the magnetic field perturbation to direct the ions. The ions exiting the cyclotron will tend to disperse as they enter the area of markedly decreased magnetic field that exists in the room around the cyclotron. Beam shaping elements 107, 109 in the extraction channel 38 redirect the ions so that they stay in a straight beam of limited spatial extent.

The magnetic field within the pole gap needs to have certain properties to maintain the beam within the evacuated chamber as it accelerates. The magnetic field index n, which is shown below,

n=−(r/B)dB/dr,

should be kept positive to maintain this “weak” focusing. Here r is the radius of the beam and B is the magnetic field. Additionally, in some implementations, the field index needs to be maintained below 0.2, because at this value the periodicity of radial oscillations and vertical oscillations of the beam coincide in a vr=2 v_zresonance. The betatron frequencies are defined by v_r=(1−n)^1/2and v_z=n^1/2. The ferromagnetic pole face is designed to shape the magnetic field generated by the coils so that the field index n is maintained positive and less than 0.2 in the smallest diameter consistent with a 250 MeV beam in the given magnetic field.

As the beam exits the extraction channel it is passed through a beam formation system 125 (FIG. 5) that can be programmably controlled to create a desired combination of scattering angle and range modulation for the beam. Beam formation system 125 may be used in conjunction with an inner gantry 601 (FIG. 14) to direct a beam to the patient.

During operation, the plates absorb energy from the applied radio frequency field as a result of conductive resistance along the surfaces of the plates. This energy appears as heat and is removed from the plates using water cooling lines 108 that release the heat in a heat exchanger 113 (FIG. 3).

Stray magnetic fields exiting from the cyclotron are limited by both the pillbox magnet yoke (which also serves as a shield) and a separate magnetic shield 114. The separate magnetic shield includes of a layer 117 of ferromagnetic material (e.g., steel or iron) that encloses the pillbox yoke, separated by a space 116. This configuration that includes a sandwich of a yoke, a space, and a shield achieves adequate shielding for a given leakage magnetic field at lower weight. In some implementations, the synchrocyclotron may have an active return system to reduce stray magnetic fields. An example of an active return system is described in U.S. patent application Ser. No. 13/907,601, which was filed on May 31, 2013, the contents of which are incorporated herein by reference.

As mentioned, the gantry allows the synchrocyclotron to be rotated about the horizontal rotational axis 532. The truss structure 516 has two generally parallel spans 580, 582. The synchrocyclotron is cradled between the spans about midway between the legs. The gantry is balanced for rotation about the bearings using counterweights 122, 124 mounted on ends of the legs opposite the truss.

The gantry is driven to rotate by an electric motor mounted to one or both of the gantry legs and connected to the bearing housings by drive gears . The rotational position of the gantry is derived from signals provided by shaft angle encoders incorporated into the gantry drive motors and the drive gears.

At the location at which the ion beam exits the cyclotron, the beam formation system 125 acts on the ion beam to give it properties suitable for patient treatment. For example, the beam may be spread and its depth of penetration varied to provide uniform radiation across a given target volume. The beam formation system can include passive scattering elements as well as active scanning elements.

All of the active systems of the synchrocyclotron (the current driven superconducting coils, the RF-driven plates, the vacuum pumps for the vacuum acceleration chamber and for the superconducting coil cooling chamber, the current driven particle source, the hydrogen gas source, and the RF plate coolers, for example), may be controlled by appropriate synchrocyclotron control electronics (not shown), which may include, e.g., one or more computers programmed with appropriate programs to effect control.

The control of the gantry, the patient support, the active beam shaping elements, and the synchrocyclotron to perform a therapy session is achieved by appropriate therapy control electronics (not shown).

As shown in FIGS. 1, 11, and 12, the gantry bearings are supported by the walls of a cyclotron vault 524. The gantry enables the cyclotron to be swung through a range 520 of 180 degrees (or more) including positions above, to the side of, and below the patient. The vault is tall enough to clear the gantry at the top and bottom extremes of its motion. A maze 146 sided by walls 148, 150 provides an entry and exit route for therapists and patients. Because at least one wall 152 is not in line with the proton beam directly from the cyclotron, it can be made relatively thin and still perform its shielding function. The other three side walls 154, 156, 150/148 of the room, which may need to be more heavily shielded, can be buried within an earthen hill (not shown). The required thickness of walls 154, 156, and 158 can be reduced, because the earth can itself provide some of the needed shielding.

Referring to FIGS. 12 and 13, for safety and aesthetic reasons, a therapy room 160 may be constructed within the vault. The therapy room is cantilevered from walls 154, 156, 150 and the base 162 of the containing room into the space between the gantry legs in a manner that clears the swinging gantry and also maximizes the extent of the floor space 164 of the therapy room. Periodic servicing of the accelerator can be accomplished in the space below the raised floor. When the accelerator is rotated to the down position on the gantry, full access to the accelerator is possible in a space separate from the treatment area. Power supplies, cooling equipment, vacuum pumps and other support equipment can be located under the raised floor in this separate space. Within the treatment room, the patient support 170 can be mounted in a variety of ways that permit the support to be raised and lowered and the patient to be rotated and moved to a variety of positions and orientations.

In system 602 of FIG. 14, a beam-producing particle accelerator of the type described herein, in this case synchrocyclotron 604, is mounted on rotating gantry 605. Rotating gantry 605 is of the type described herein, and can angularly rotate around patient support 606. This feature enables synchrocyclotron 604 to provide a particle beam directly to the patient from various angles. For example, as in FIG. 14, if synchrocyclotron 604 is above patient support 606, the particle beam may be directed downwards toward the patient. Alternatively, if synchrocyclotron 604 is below patient support 606, the particle beam may be directed upwards toward the patient. The particle beam is applied directly to the patient in the sense that an intermediary beam routing mechanism is not required. A routing mechanism, in this context, is different from a shaping or sizing mechanism in that a shaping or sizing mechanism does not re-route the beam, but rather sizes and/or shapes the beam while maintaining the same general trajectory of the beam.

Further details regarding an example implementation of the foregoing system may be found in U.S. Pat. No. 7,728,311, filed on Nov. 16, 2006 and entitled “Charged Particle Radiation Therapy”, and in U.S. patent application Ser. No. 12/275,103, filed on Nov. 20, 2008 and entitled “Inner Gantry”. The contents of U.S. Pat. No. 7,728,311 and in U.S. patent application Ser. No. 12/275,103 are incorporated herein by reference. In some implementations, the synchrocyclotron may be a variable-energy device, such as that described in U.S. patent application Ser. No. 13/916,401, filed on Jun. 12, 2013, the contents of which are incorporated herein by reference.

EXAMPLE IMPLEMENTATIONS

Referring to FIG. 15, an example control system 1500 may be used to control the example particle therapy system described above, e.g., with respect to FIGS. 1-14. The control system 155 may contain a Therapy Control Computer (TCC) 1502 that can include a user interface, a Master Control Computer (MCC) 1508 for processing machine instructions in real-time, and I/O modules 1510, 1522 that can send machine instructions to components of the particle accelerator.

In some examples, the TCC 1502 is networked to a hospital so the TCC 1502 can receive patent prescriptions 1504 from the hospital before treatment and send treatment records 1506 to the hospital after treatment. The TCC 1502 can also translate a received patient prescription 1504 into machine parameters that can be understood by a Master Control Computer (MCC) 1508.

The MCC 1508 can include a real-time operating system 1508a. A real-time operating system 1508a is an operating system that serves real-time requests. For example, a non-real-time operating systems may delay serving a request if it is busy doing something else.

The MCC 1508 can be configured to receive machine parameters from the TCC 1502. The MCC 1508 can translate the machine parameters into specific machine instructions that can be understood by one or more slow input/output modules 1510 and one or more fast input/output modules 1522, described in more detail below. The MCC 1508, with the aid of the real-time operating system 1508a, can send machine instructions to the slow 1510 and fast I/O modules 1522 at specified times in a specified order.

The slow I/O modules 1510 can be used to send machine instructions to aspects of the particle accelerator that do not require relatively fast transmission. In this context, “slow” refers to an operational speed that is less than a “fast” operational speed, and “fast refers to an operational speed that is greater than “slow” operational speed. The terms “slow” and “fast” are not intended to refer to, or to imply, any specific operational speeds and are relative terms, not absolute values.

In some examples, the slow I/O modules 1510 are programmable logic controllers with speeds in the order of milliseconds. For example, a machine instruction may take more than 1 ms to arrive at the particular component. Slow I/O modules 1510 can be configured to send machine instructions to one or more motor controllers 1530.

In some examples, the slow I/O modules 1510 send machine instructions to one or more motor controllers 1530. In an example, the motor controllers 1530 can control motors that are part of a field shaping wheel system 1512, a scatterer system 1514, a rotating capacitor system 1516, a modular wheel control system 1518, or a gantry control system 1520, although the motor controllers can be part of any system that uses a motor.

Referring to FIG. 16, an example field shaping wheel system 1512 can be used to shape the particle beam to a desired shape. The field shaping wheel system 1512 can include a wheel rack 1608, a wheel chamber 1612, wheels 1610, and wheel motors 1606a-c. Each wheel 1610 alters the shape of the magnetic field in a different way. An example slow I/O module 1510a can send machine instructions to motor controllers 1530a-c depending on which wheel 1610 is appropriate (e.g., based on the translated prescription). Each motor controller 1530a-c can control one wheel motor 1606a-c. Wheel motor 1606a can move the wheel rack 1608 side to side until the selected wheel 1610 is situated below the wheel chamber 1612. Once the selected wheel 1610 is horizontally aligned, wheel motor 1606b can move the wheel up into the wheel chamber 1612. Once the selected wheel 1610 is situated in the wheel chamber 1612, wheel motor 1606c can rotate it. Different rotational positions can have different effects on the shape of the magnetic field that the particle beam experiences.

As explained above, the beam formation system (125 of FIG. 5) can create a desired combination of scattering angle and range modulation for the particle beam. Referring to FIG. 17, the output particle beam 1704 may have a Gaussian profile (with a majority of particles at the center of the beam) after it passes through the extraction channel (and the modulator wheel, described below). A scatterer 1702a can reshape the particle beam so that the particle beam has a substantially constant width (w). For example, the particle beam may have a circular cross-section. In this implementation, scatterer 1702a is a scattering foil, all or part of which may be made of a metal, such as lead. As shown, scatterer 1702a has a side that is convex in shape, and includes more lead at its edges than at its center. To achieve a larger field beam size, thicker lead may be used, and vice versa. In this regard, the particle therapy system may include multiple scatterers 1702a-e, which may be switched into, or out of, the path of the particle beam in order to achieve a particle beam field size (cross-sectional area).

Different treatments require different scattering angles and range modulations. The scatterer system 1514 can be used to place the appropriate scatterer 1702a-e in the particle beam path. In an example, the scatterer system 1514 can include one or more motors 1706 configured to place different scatterers 1702a-e in the particle beam path in a way similar to the field shaping wheel system 1512. An example slow I/O module 1510b can send machine instructions to a motor controller 1530d depending on which scatterer 1702a-e is appropriate (e.g., based on the translated prescription). The motor controller 1530d can control the motor 1706 such that the motor 1706 places the appropriate scatterer 1702a-e in the beam formation system 125.

As explained above, a rotating capacitor can be used tune the RF structure during the frequency sweep. In an example, a rotating capacitor system 1516 can be configured to rotate some of the blades of the rotating capacitor to an appropriate position. The rotating capacitor system 1516 can include one or more motors that can control the rotating capacitor in a way similar to the field shaping wheel system 1512. An example slow I/O module 1510 can send machine instructions to motor controllers to rotate the capacitor at a fixed speed. An associated fast I/O system can coordinate the rotational speed of the modulator wheel with the rotational speed of the capacitor to insure the beam pulses from the synchrocyclotron are uniformly distributed on the modulator wheel azimuthally

As explained above, the gantry enables the particle accelerator to be rotated around a patient position. The gantry control system 1520 can be used to rotate the gantry into the appropriate position (e.g., to apply treatment at the desired angle). In an example, the gantry control system 1520 can include one or more motors configured to rotate the gantry to the appropriate position in a way similar to systems 1512, 1514, and 1516. An example slow I/O module 1510 can send machine instructions to motor controllers 1530 depending on what gantry position is appropriate (e.g., based on the translated prescription). The motor controllers 1530 can control the motors such that the motors rotate the gantry into the correct position.

Downstream from (e.g., after) the extraction channel, various devices are used to affect the particle beam output. One such device is configured to spread-out Bragg peaks of the particle beam to achieve a substantially uniform particle beam dose at a range of depths within the patient. As described in wikipedia.org, “[w]hen a fast charged particle moves through matter, it ionizes atoms of the material and deposits a dose along its path. A peak occurs because the interaction cross section increases as the charged particle's energy decreases.” “The Bragg peak is a pronounced peak on the Bragg curve which plots the energy loss of ionizing radiation during its travel through matter. For protons . . . the peak occurs immediately before the particles come to rest.” FIG. 18 is an example Bragg curve showing a Bragg peak 900 for a particular dose of proton therapy and depth.

To achieve a relatively uniform dose of particle therapy at a range of depths, a modulator device is configured to move Bragg peaks of the particle beam along the graph of FIG. 18 and to change the intensity of the Bragg peaks at the moved locations. Because particle therapy is cumulative, the resulting dosages may be added to obtain a substantially uniform dose. For example, referring to FIG. 18, the dosage at point 901 is the sum of doses at point 902 on Bragg curve 903, at point 904 on Bragg curve 905, and at point 906 on Bragg curve 907. Ideally, the result is a substantially uniform dose from depths 908a to 908b. This is referred to as a “spread-out Bragg peak”, which extends depth-wise into a patient.

In some implementations, the modulator device used to spread-out the Bragg peaks is a structure, such as a modulator wheel, having different thicknesses at different locations along its circumference. Accordingly, the modulator wheel is rotatable in the path of, and relative to, the particle beam in order to provide the appropriate amount of particle therapy for a particular depth and area.

FIG. 19 shows a perspective view of an example modulator wheel 910 and FIG. 20 shows a top view of modulator wheel 910. As shown in the figures, the modulator wheel 910 has numerous steps 911, each with a different thickness (e.g., varying from zero or substantially zero thickness to a thickness on the order of centimeters or more). The thicknesses are used to vary the depth of corresponding Bragg peaks. For example, the least amount of thickness produces a Bragg peak with the most depth, the greatest amount of thickness produces a Bragg peak with the least depth, and so forth. As shown in FIG. 20 the angles (e.g., 912, 913, etc.) of the various steps also vary, resulting in different circumferential lengths for at least some of, and in some cases all of, the steps. The angle of each step adjusts how much the corresponding Bragg peak subtends within the patient. For example, the Bragg peak with the most intensity (e.g., Bragg peak 900 of FIG. 18) is the one that subtends the most. Accordingly, its corresponding step 914 has the largest angular extent. The Bragg peak with the next most intensity (e.g., Bragg peak 904 of FIG. 18) is the one that subtends the next most. Accordingly, its corresponding step 915 has the next largest angular extent; and so forth.

The modulator wheel may have constant, substantially constant, or variable rotation in order to provide the appropriate Bragg peak spreading for a prescription. In some implementations, the particle therapy system may include more than one modulator wheel of the type shown in FIGS. 27 and 28. The modulator wheels may be switchable into, and out of, the beam path by a modulator wheel control system (1518 of FIG. 15) in order to achieve a desired particle beam dose at a particular patient depth. For example, a first modulator wheel may be used for a first depth or range of depths (e.g., 10 cm to 15 cm); a second modulator wheel may be used for a second depth or range of depths (e.g., 15 cm to 20 cm); a third modulator wheel may be used for a third depth or range of depths (e.g., 20 cm to 25 cm); and so forth. In some implementations, there may be twelve modulator wheels, each of which may be calibrated for a different depth range; however, in other implementations, more or less than twelve modulator wheels may be used. Treatment depth is also dependent upon the particle beam intensity, which is a function of the ion (or particle) source pulse width, as described below.

The modulator wheels may be designed to provide uniform spread-out Bragg peaks from a maximum depth to the surface of a patient (e.g., to the outer layer of the patient's skin). To customize the depth of dosage, Bragg peaks in undesired locations (e.g., in area 917 in FIG. 18) may be “turned-off”. This may be done by turning-off the RF source, turning-off the particle source, or turning-off both at an appropriate time during each rotation of the modulator wheel.

Particle source pulse width also has an effect on spread-out Bragg peak uniformity. As background, the amount of time that a particle source is intermittently (e.g., periodically) activated is varied, thereby providing the plasma column for different periods of time and enabling extraction of different numbers of particles. For example, if the pulse width is increased, the number of particles extracted increases and, if the pulse width decreases, the number of particles extracted decreases. In some implementations, there is a linear relationship between the time that the particle source is on and the intensity of the particle beam. For example, the relationship may be one-to-one plus an offset. In an example implementation, the particle source may be pulsed within a frequency window that occurs during a frequency sweep between a maximum frequency of about 135 MHz and a minimum frequency of about 95 MHz or 90 MHz. For example, the particle source may be pulsed between 132 MHz and 131 MHz for a period of time. In an implementation, this period of time is about 40 us; however, these values may vary or be different in other implementations. Failing to pulse the particle source outside of the frequency window can inhibit extraction of particles from the plasma column.

FIG. 21 is a graph showing the voltage sweep in the resonant cavity over time from a maximum frequency (e.g., 135 MHz) to a minimum frequency (e.g., 90 MHz or 95 MHz). The extraction window 920 occurs, in this example, between 132 MHz and 131 MHz. The width of pulse 921 (the particle source pulse width) may be varied (e.g., by controlling the “on” time of the particle source) to control the intensity of the particle beam output by the particle accelerator.

Particle source pulse widths may be adjustable in order to achieve substantial uniformity in spread-out Bragg peaks. In this regard, various factors, such as particle beam intensity, may contribute to the depth at which Bragg peaks penetrate a patient. A selected modulator wheel can produce different Bragg curves for different depths. For example, FIG. 22 shows Bragg curves for three different depths. Bragg curve 950 is for the nominal (or predefined) depth for a modulator wheel; Bragg curve 951 is for the maximum depth for the modulator wheel; and Bragg curve 952 is for the minimum depth for the modulator wheel. Ideally, the spread-out Bragg peaks should be at about the nominal level regardless of depth.

As shown in FIG. 22, Bragg curves 951 and 952 have spread-out Bragg peaks that are sloped. For Bragg curve 952, the slope is positive; and for Bragg curve 951 the slope is negative. To more closely approximate the nominal Bragg peak level at point b, the intensity of the particle beam is be increased at point a (to raise the Bragg peak at point a to the level at point b), and the intensity of the particle beam is be decreased at point c (to lower the Bragg peak at point c to the level of point b). The intensity of the particle beam is also be adjusted at points preceding a and c to either raise or lower the Bragg peaks at those points so that they coincide, at least to some degree, with the corresponding level of the nominal Bragg peak. The intensity of the particle beam may be changed by changing the particle source pulse width. However, different points along Bragg curves 951 and 952 require different amounts of adjustment in order to approximate the nominal spread-out Bragg peak of curve 950. Accordingly, in each instance, the pulse widths may be varied based on rotation of the modulator wheel. For example, at a point a when the modulator wheel impacts the particle beam, the pulse width may be increased more than at points preceding a along Bragg curve 951. Similarly, at a point c when the modulator wheel impacts the particle beam, the pulse width may be decreased more than at points preceding c along Bragg curve 952. For example, FIG. 23 is a plot showing the relationship between pulse width and rotational angle of the modulator wheel for Bragg curves 950, 951 and 952. Values have been omitted, since they are case specific.

Variations in pulse-width can be determined by obtaining the appropriate pulse widths at the beginning and ending of a Bragg peak, and linearly interpolating between the two to obtain variations in between. Other processes also may be used, as described below. To increase or decrease an overall dose, all pulse widths may be increased or decreased by a specified factor.

The modulator wheels may be switchable into, or out of, the beam path, as noted above. In an example, the modulator wheel control system (1518 of FIG. 15) can include one or more motors and a modulator wheel rack. An example slow I/O module 1510 can send machine instructions to motor controllers 1530 depending on which modulator wheel is appropriate (e.g., based on the translated prescription). Each motor controller 1530 can control a motor. For example, a motor can move the modulator wheel rack side to side until the selected modulator wheel is in position, and another motor can move the modulator wheel into, or out of, the beam path. In other implementations, the modulator wheel rack may be below the beam path, and an appropriate modulator wheel may be positioned proximate the beam path, and thereafter moved into the beam path by another motor.

Referring back to FIG. 15, a fast I/O module 1522 can be used to control components of the particle accelerator that require relatively fast transmission (e.g., the particle source 1524 and the RF voltage source). The fast I/O module can include a microprocessor 1522a for communicating with the real-time operating system 1508a of the MCC 1508, and a field-programmable gate array (FPGA) 1522b for sending and receiving information to/from the particle accelerator components. A modulator wheel communication line can also send information to the FPGA (1522b) pertaining to the modulator wheel. In an example, the modulator wheel communication line 1528 is an optical fiber 1528 that includes a sensor configured to monitor the modulator wheel.

As explained above, the modulator wheels may be configured to provide uniform spread-out Bragg peaks from a maximum depth to the surface of a patient (e.g., to the outer layer of the patient's skin). To affect the dosage, the particle source may be turned on and off at appropriates time during each rotation of the modulator wheel. This process is known as “pulse blanking”.

In some implementations, the particle source has a pulse frequency of about 500 pulses-per-second, with about 10 nano-amperes (nA) of current per-pulse. In other implementations, the number of pulses-per-second, and current per-pulse may be different than these numbers. In some implementations, a modulator wheel rotates such that each step of the modulator wheel (corresponding one of plural different thicknesses) receives multiple pulses on each step during rotation. The dosage for each step corresponds to the number of pulses received by that step.

The number of pulses applied to a target corresponds to the radiation dose at the target, and can have an effect on spread-out Bragg peak uniformity. More specifically, modulator wheels may be calibrated to provide dosage at specific tissue depths. For example, the thicknesses of wheel steps may be calibrated, based on an expected dose, to provide spread-out Bragg peaks over a range of depths, ideally to result in a uniform dose approximating something like that shown in FIG. 18. However, in practice, variations in tissues and materials (for example) may result in Bragg curves (i.e., depth dose distributions) that are non-uniform or that are sloped. FIG. 22, described above, shows examples of Bragg curves that are sloped, which could possibly result from such modulator wheels.

More specifically, as explained above, a selected modulator wheel can produce different Bragg curves for different tissue depths. For example, FIG. 22 shows Bragg curves for three different depths. Bragg curve 950 is for the nominal (or predefined) depth for a modulator wheel; Bragg curve 951 is for the maximum depth for the modulator wheel; and Bragg curve 952 is for the minimum depth for the modulator wheel. Ideally, the spread-out Bragg peaks should be at about the nominal level regardless of depth.

As shown in FIG. 22, Bragg curves 951 and 952 have spread-out Bragg peaks that are sloped. For Bragg curve 952, the slope is positive; and for Bragg curve 951 the slope is negative. To more closely approximate the nominal Bragg peak level at point b, the relative dosage of the particle beam (e.g., the number of pulses) may be increased at point a (to raise the Bragg peak at point a to the level at point b), and the relative dosage (e.g., the number of pulses) of the particle beam may be decreased at point c (to lower the Bragg peak at point c to the level of point b). The relative dosages of the particle beam may also be adjusted at points preceding a and c to either raise or lower the Bragg peaks at those points so that they coincide, at least to some degree, with the corresponding level of the nominal Bragg peak. In this regard, different points along Bragg curves 951 and 952 require different amounts of adjustment in order to approximate the nominal spread-out Bragg peak of curve 950. Accordingly, in each instance, the relative dosage (e.g., the number of pulses) may be varied based on, and corresponding to, rotation of the modulator wheel. For example, at a point a when the modulator wheel impacts the particle beam, the relative dosage (e.g., number of pulses) may be increased more than at points preceding a along Bragg curve 951. Similarly, at a point c when the modulator wheel impacts the particle beam, the relative dosage (e.g., number of pulses) may be decreased more than at points preceding c along Bragg curve 952. The dosage applications are analogous to FIG. 23, which is described above for pulse width variations

Variations in dosage to obtain uniform Bragg curves can be determined by obtaining the dosages at the beginning and ending of a Bragg peak, and linearly interpolating between the two to obtain variations in between. This information may be obtained as part of a calibration process. Other processes also may be used, as described below.

To increase or decrease an overall dose, the particle source and/or other feature(s) of the particle therapy system may be used to control the number of output pulses. For example, the particle source may be turned off to reduce the number of output of pulses to the modulator wheel, and the particle source may be turned on to increase the number of output pulse of the particle beam to the modulator wheel. This control may be performed at a certain step or steps (e.g., sectors) of the modulator wheel to obtain the desired result, e.g., increased or decreased dosage and, therefore, an increase or decrease in the slope of the corresponding Bragg curve. Dosage may also be applied or withheld to correct for holes or spikes in the Bragg curves. Control over the various aspects of the system may be performed by the slow and fast I/O modules described above. In other implementations, different control systems may be used.

As noted, in some implementations, the number of pulses may be varied by turning-on or turning-off the particle source at appropriate times during rotation of the modulator wheel. In some implementations, other features are used to control the number of pulses that are applied to particular sectors of the modulator wheel. For example, the RF voltage sweep may be interrupted intermittently, thereby reducing the number of pulses (since a pulse is typically output per sweep). To increase the number of pulses, the rate of the sweep may be increased. In another example, additional hardware may be used to control the number of pulses. For example, a steering mechanism, such as a kicker magnet, may be used to reduce the output of pulses for particular rotations of the modulator wheel. In some implementations, a kicker magnet (or other structure) may direct a set (e.g., every other, every third, and so forth) of pulses to an absorber material, thereby preventing their output to the irradiation target.

To obtain a flat, or substantially flat, Bragg curve, as explained herein it may be necessary to increase or decrease the relative number of pulses applied to particular sectors of a modulator wheel. The increase or decrease may be relative to amounts of pulses applied to other sectors of the modulator wheel. For example, a decrease in the number of pulses applied to all sectors of a modulator wheel but not to one sector has a similar effect as an increase in the number of pulses applied to that one sector of the modulator wheel. Such relative changes to the applied numbers of pulses may be used to obtain the appropriate increase and decreases to change a Bragg curve. In cases where the numbers of pulses have been decreased to obtain a relative increase in one sector, the overall dose applied may be reduced. In those situations, the particle therapy system may require a longer irradiation time to achieve the required overall dosage for a particular target.

In some implementations, the particle therapy system may include a scanning system to scan the particle beam across a cross-section of an irradiation target. This is done at different depths to treat the entire irradiation target. In implementations that involve scanning, pulse blanking of the type described herein may be used on a spot-by-spot basis. That is, during scanning, a particle beam is applied at a spot, then the particle beam is moved (typically by a magnet) to a next spot on the irradiation target. Pulse blanking may be used to control the number of pulses applied to each spot. Generally, spot scanning involves applying irradiation at discrete spots on an irradiation target and raster scanning involves moving a radiation spot across the radiation target. The concept of spot size therefore applies for both raster and spot scanning.

Referring back to FIG. 19, the example modulator wheel 910 may have multiple markings 916 around its edge. The markings 916 can be any shape and can have any configuration. Particular markings 916 can signify particular modulator wheel 910 positions. In an example, the exact position of the modulator wheel 910 can be determined by identifying the markings 916. In another example, the markings 916 are configured such that the rotational speed of the modulator wheel 910 can be determined by only looking at the markings 916.

A first end of the optical fiber 1528 (e.g., the end that includes the sensor) can be situated in a position where it can detect the markings 916 on the modulator wheel 910. A second end of the optical fiber 1528 can be connected to the FPGA 1522b and be configured to communicate information pertaining to the modulator wheel 910 (e.g., its position and rotational speed).

The FPGA 1522b may also be configured to send and receive information from the particle source 1524 and the RF voltage source 1526. As explained above, the depth of dosage (e.g., based on the translated prescription) can be customized by “turning-off” Bragg peaks in undesired locations (e.g., in area 917 in FIG. 18). This may be done by turning-off the RF source, turning-off the particle source, or turning-off both at an appropriate time during each rotation of the modulator wheel 910. The FPGA 1522b can communicate the information the FPGA 1522b receives from the optical fiber 1528 to the microprocessor 1522a (which in turn communicated with the real-time operating system 1508a of the MCC 1508) and receive instructions from the microprocessor 1522a regarding particle source 1524 and RF voltage source 1526 control. For example, the FPGA 1522b may tell the particle source 1524 and/or the RF voltage source 1526 to turn on/off when the modulator wheel 910 is in a particular position or positions. The FPGA 1522b may also tell the particle source 1524 how long to make the particle source pulse widths based on the rotational position of the modulator wheel.

As mentioned above, the fast I/O module 1522 can also receive information from the particle source 1524 and the RF voltage source 1526. A fast I/O module 1522 is desirable for controlling these components because their operation is time sensitive. Referring back to FIG. 21, the extraction window 920 is created by pulsing the particle source over a particular frequency range. In some examples, this frequency range is very small (e.g., less than a 1 MHz window). The fast I/O module 1522 can also receive information from the RF voltage source 1526 and the particle source 1524 in addition to the information it receives about the modulator wheel 910. The RF voltage source 1526 can continuously communicate its frequency to the fast I/O module 1522. The fast I/O module can then tell the particle source 1524 to turn on when it learns that the RF voltage source is at a particular frequency or the modulator wheel is at a particular location, and to turn off when it learns that the RF voltage source is at a particular frequency or the modulator wheel is at a particular location. The fast I/O module 1522 can also use received information (e.g., the rotational position of the modulator wheel) to tell the particle source 1524 how long to make the particle source pulse widths.

Aspects of the control system are system specific and may vary depending on the type of treatment (e.g., the prescription).

Elements of different implementations described herein may be combined to form other implementations not specifically set forth above. Elements may be left out of the processes, systems, apparatus, etc., described herein without adversely affecting their operation. Various separate elements may be combined into one or more individual elements to perform the functions described herein.

The example implementations described herein are not limited to use with a particle therapy system or to use with the example particle therapy systems described herein. Rather, the example implementations can be used in any appropriate system that directs accelerated particles to an output.

Additional information concerning the design of an example implementation of a particle accelerator that may be used in a system as described herein can be found in U.S. Provisional Application No. 60/760,788, entitled “High-Field Superconducting Synchrocyclotron” and filed Jan. 20, 2006; U.S. patent application Ser. No. 11/463,402, entitled “Magnet Structure For Particle Acceleration” and filed Aug. 9, 2006; and U.S. Provisional Application No. 60/850,565, entitled “Cryogenic Vacuum Break Pneumatic Thermal Coupler” and filed Oct. 10, 2006, all of which are incorporated herein by reference.

The following applications, all of which are filed on the same date as the subject application (entitled “CONTROL SYSTEM FOR A PARTICLE ACCELERATOR” (Application No. 61/707,645)), are incorporated by reference into the subject application: the U.S. Provisional Application entitled “CONTROLLING INTENSITY OF A PARTICLE BEAM” (Application No. 61/707,466 filed on Sep. 29, 2012), the U.S. Provisional Application entitled “ADJUSTING ENERGY OF A PARTICLE BEAM” (Application No. 61/707,515, filed on Sep. 28, 2012), the U.S. Provisional Application entitled “ADJUSTING COIL POSITION” (Application No. 61/707,548, filed on Sep. 28, 2012), the U.S. Provisional Application entitled “FOCUSING A PARTICLE BEAM USING MAGNETIC FIELD FLUTTER” (Application No. 61/707,572, filed on Sep. 28, 2012), the U.S. Provisional Application entitled “MAGNETIC FIELD REGENERATOR” (Application No. 61/707,590, filed on Sep. 28, 2012), the U.S. Provisional Application entitled “FOCUSING A PARTICLE BEAM” (Application No. 61/707,704, filed on Sep. 28, 2012), and the U.S. Provisional Application entitled “CONTROLLING PARTICLE THERAPY (Application No. 61/707,624, filed on Sep. 28, 2012).

The following are also incorporated by reference into the subject application: U.S. Pat. No. 7,728,311 which issued on Jun. 1, 2010, U.S. patent application Ser. No. 11/948,359 which was filed on Nov. 30, 2007, U.S. patent application Ser. No. 12/275,103 which was filed on Nov. 20, 2008, U.S. patent application Ser. No. 11/948,662 which was filed on Nov. 30, 2007, U.S. Provisional Application No. 60/991,454 which was filed on Nov. 30, 2007, U.S. Pat. No. 8,003,964 which issued on Aug. 23, 2011, U.S. Pat. No. 7,208,748 which issued on Apr. 24, 2007, U.S. Pat. No. 7,402,963 which issued on Jul. 22, 2008, U.S. patent application Ser. No. 13/148,000 filed Feb. 9, 2010, U.S. patent application Ser. No. 11/937,573 filed on Nov. 9, 2007, U.S. patent application Ser. No. 11/187,633, titled “A Programmable Radio Frequency Waveform Generator for a Synchrocyclotron,” filed Jul. 21, 2005, U.S. Provisional Application No. 60/590,089, filed on Jul. 21, 2004, U.S. patent application Ser. No. 10/949,734, titled “A Programmable Particle Scatterer for Radiation Therapy Beam Formation”, filed Sep. 24, 2004, and U.S. Provisional Application No. 60/590,088, filed Jul. 21, 2005.

Any features of the subject application may be combined with one or more appropriate features of the following: the U.S. Provisional Application entitled “CONTROLLING INTENSITY OF A PARTICLE BEAM” (Application No. 61/707,466 filed on Sep. 29, 2012), the U.S. Provisional Application entitled “ADJUSTING ENERGY OF A PARTICLE BEAM” (Application No. 61/707,515, filed on Sep. 28, 2012), the U.S. Provisional Application entitled “ADJUSTING COIL POSITION” (Application No. 61/707,548, filed on Sep. 28, 2012), the U.S. Provisional Application entitled “FOCUSING A PARTICLE BEAM USING MAGNETIC FIELD FLUTTER” (Application No. 61/707,572, filed on Sep. 28, 2012), the U.S. Provisional Application entitled “MAGNETIC FIELD REGENERATOR” (Application No. 61/707,590, filed on Sep. 28, 2012), the U.S. Provisional Application entitled “FOCUSING A PARTICLE BEAM” (Application No. 61/707,704, filed on Sep. 28, 2012), the U.S. Provisional Application entitled “CONTROLLING PARTICLE THERAPY (Application No. 61/707,624, filed on Sep. 28, 2012), U.S. Pat. No. 7,728,311 which issued on Jun. 1, 2010, U.S. patent application Ser. No. 11/948,359 which was filed on Nov. 30, 2007, U.S. patent application Ser. No. 12/275,103 which was filed on Nov. 20, 2008, U.S. patent application Ser. No. 11/948,662 which was filed on Nov. 30, 2007, U.S. Provisional Application No. 60/991,454 which was filed on Nov. 30, 2007, U.S. patent application Ser. No. 13/907,601, which was filed on May 31, 2013, U.S. patent application Ser. No. 13/916,401, filed on Jun. 12, 2013, U.S. Pat. No. 8,003,964 which issued on Aug. 23, 2011, U.S. Pat. No. 7,208,748 which issued on Apr. 24, 2007, U.S. Pat. No. 7,402,963 which issued on Jul. 22, 2008, U.S. patent application Ser. No. 13/148,000 filed Feb. 9, 2010, U.S. patent application Ser. No. 11/937,573 filed on Nov. 9, 2007, U.S. patent application Ser. No. 11/187,633, titled “A Programmable Radio Frequency Waveform Generator for a Synchrocyclotron,” filed Jul. 21, 2005, U.S. Provisional Application No. 60/590,089, filed on Jul. 21, 2004, U.S. patent application Ser. No. 10/949,734, titled “A Programmable Particle Scatterer for Radiation Therapy Beam Formation”, filed Sep. 24, 2004, and U.S. Provisional Application No. 60/590,088, filed Jul. 21, 2005.

Except for the provisional application from which this patent application claims priority and the documents incorporated by reference above, no other documents are incorporated by reference into this patent application.

Other implementations not specifically described herein are also within the scope of the following claims.

Claims

1. A particle therapy system comprising: a particle accelerator to output a particle beam, comprising: a particle source to provide pulses of ionized plasma to a cavity, each pulse of the particle source having a pulse width corresponding to a duration of operation of the particle source to produce the corresponding pulse, the particle beam being based on the pulses of ionized plasma; anda modulator wheel having different thicknesses, each thickness extending across a different circumferential length of the modulator wheel, the modulator wheel being arranged to receive a precursor to the particle beam and configured to create a spread-out Bragg peak for the particle beam;one or more first input/output (I/O) modules operable at a first speed, the one or more first I/O modules being configured to send machine instructions to one or more motor controllers, at least one motor controller for controlling the modulator wheel;one or more second I/O modules operable at a second speed that is greater than the first speed, at least one of the second I/O modules being configured to send machine instructions to the particle source so that pulse widths of the particle source vary with rotational positions of the modulator wheel.
2. The particle therapy system of claim 1, further comprising; a therapy control computer programmed to receive prescription information from a hospital, to translate the prescription information to machine information, and to send treatment records to the hospital; anda master control computer having a real-time operating system, the master control computer programmed to receive machine information from the therapy control computer, to translate the machine information into machine instructions, and send the machine instructions to one or more of the first I/O modules and the second I/O modules.
3. The particle therapy system of claim 2, further comprising an optical fiber over which is monitored a rotational speed and position of the modulator wheel.
4. The particle therapy system of claim 1, wherein the first I/O modules comprise programmable logic controllers (PLC).
5. The particle therapy system of claim 4, wherein at least one of the PLCs is programmed to send machine instructions to motor controllers for controlling a field shaping wheel system for shaping the particle beam prior to output.
6. The particle therapy system of claim 4, wherein at least one of the PLCs is programmed to send machine instructions to a motor controller for controlling a scattering system for collimating the particle beam prior to output.
7. The particle therapy system of claim 4, further comprising: a radio frequency (RF) system to sweep RF frequencies through the cavity to extract particles from a plasma column produced by the particle source, the RF system comprising a rotating capacitor;wherein at least one of the PLCs is programmed to send machine instructions to a motor controller that controls the rotating capacitor.
8. The particle therapy system of claim 1, wherein a speed of the first I/O modules is on the order of milliseconds and a speed of the second I/O modules is on the order of one or more hundreds of nanoseconds.
9. The particle therapy system of claim 4, further comprising: a rotatable gantry on which the particle accelerator is mounted;wherein at least one of the PLCs is programmed to send machine instructions to a motor controller that controls the rotatable gantry.
10. The particle therapy system of claim 4, wherein two or more of the PLCs are configured to communicate with one another.
11. The particle therapy system of claim 1, wherein the second I/O modules comprise field-programmable gate arrays (FPGA).
12. The particle therapy system of claim 11, further comprising: a circuit board comprising a microprocessor;at least one of the FPGAs being on the circuit board and in communication with the microprocessor;wherein the microprocessor is programmed to communicate with a control computer.
13. The particle therapy system of claim 11, further comprising: a radio frequency (RF) system to sweep RF frequencies through the cavity to extract particles from a plasma column produced by the particle source;wherein at least one of the FPGAs comprises an RF control module, the RF control module being configured to receive information about a rotation of the modulator wheel and, based thereon, to coordinate operational aspects of the particle source and the RF system.
14. The particle therapy system of claim 13, wherein coordinating operational aspects of the particle source and the RF system comprises turning the particle source on or off based on a rotational position of the modulator wheel, and turning the RF system on or off based on a rotational position of the modulator wheel.
15. The particle therapy system of claim 14, wherein the RF control module is further configured to send machine instruction to the particle source to turn-on when an RF voltage is at a certain frequency and to turn-off when the RF voltage is at a certain frequency.
16. The control system of claim 14, wherein coordinating operational aspects of the particle source comprises specifying pulse widths during turn-on times of the particle source.
17. A particle therapy system comprising: a particle accelerator to output a particle beam, comprising: a particle source to provide pulses of ionized plasma to a cavity, each pulse of the particle source having a pulse width corresponding to a duration of operation of the particle source to produce the corresponding pulse, the particle beam being based on the pulses of ionized plasma; anda modulator wheel having different thicknesses, each thickness extending across a different circumferential length of the modulator wheel, the modulator wheel being arranged to receive a precursor to the particle beam and being configured to create a spread-out Bragg peak for the particle beam;wherein the particle therapy system is configured so that pulse widths of the particle source vary with rotational positions of the modulator wheel.

CROSS-REFERENCE TO RELATED APPLICATION

Priority is hereby claimed to U.S. Provisional Application No. 61/707,645, which was filed on Sep. 28, 2012. The contents of U.S. Provisional Application No. 61/707,645 are hereby incorporated by reference into this disclosure.

US Referenced Citations (591)

Number	Name	Date	Kind
2280606	Van et al.	Apr 1942	A
2492324	Salisbury	Dec 1949	A
2615129	McMillan	Oct 1952	A
2616042	Weeks	Oct 1952	A
2659000	Salisbury	Nov 1953	A
2701304	Dickinson	Feb 1955	A
2789222	Martin	Apr 1957	A
3175131	Burleigh et al.	Mar 1965	A
3432721	Naydan et al.	Mar 1969	A
3582650	Avery	Jun 1971	A
3679899	Dimeff	Jul 1972	A
3689847	Verster	Sep 1972	A
3757118	Hodge et al.	Sep 1973	A
3868522	Bigham et al.	Feb 1975	A
3886367	Castle	May 1975	A
3925676	Bigham et al.	Dec 1975	A
2958327	Marancik et al.	May 1976	A
3955089	McIntyre et al.	May 1976	A
3958327	Marancik et al.	May 1976	A
3992625	Schmidt et al.	Nov 1976	A
4038622	Purcell	Jul 1977	A
4047068	Ress et al.	Sep 1977	A
4112306	Nunan	Sep 1978	A
4129784	Tschunt et al.	Dec 1978	A
4139777	Rautenbach	Feb 1979	A
4197510	Szu	Apr 1980	A
4220866	Symmons et al.	Sep 1980	A
4230129	LeVeen	Oct 1980	A
4256966	Heinz	Mar 1981	A
4293772	Stieber	Oct 1981	A
4336505	Meyer	Jun 1982	A
4342060	Gibson	Jul 1982	A
4345210	Tran	Aug 1982	A
4353033	Karasawa	Oct 1982	A
4425506	Brown et al.	Jan 1984	A
4490616	Cipollina et al.	Dec 1984	A
4507614	Prono et al.	Mar 1985	A
4507616	Blosser et al.	Mar 1985	A
4589126	Augustsson et al.	May 1986	A
4598208	Brunelli et al.	Jul 1986	A
4628523	Heflin	Dec 1986	A
4633125	Blosser et al.	Dec 1986	A
4641057	Blosser et al.	Feb 1987	A
4641104	Blosser et al.	Feb 1987	A
4651007	Perusek et al.	Mar 1987	A
4680565	Jahnke	Jul 1987	A
4705955	Mileikowsky	Nov 1987	A
4710722	Jahnke	Dec 1987	A
4726046	Nunan	Feb 1988	A
4734653	Jahnke	Mar 1988	A
4737727	Yamada et al.	Apr 1988	A
4739173	Blosser et al.	Apr 1988	A
4745367	Dustmann et al.	May 1988	A
4754147	Maughan et al.	Jun 1988	A
4763483	Olsen	Aug 1988	A
4767930	Stieber et al.	Aug 1988	A
4769623	Marsing et al.	Sep 1988	A
4771208	Jongen et al.	Sep 1988	A
4783634	Yamamoto et al.	Nov 1988	A
4808941	Marsing	Feb 1989	A
4812658	Koehler	Mar 1989	A
4843333	Marsing et al.	Jun 1989	A
4845371	Stieber	Jul 1989	A
4865284	Gosis et al.	Sep 1989	A
4868843	Nunan	Sep 1989	A
4868844	Nunan	Sep 1989	A
4870287	Cole et al.	Sep 1989	A
4880985	Jones	Nov 1989	A
4894541	Ono	Jan 1990	A
4896206	Denham	Jan 1990	A
4902993	Krevet	Feb 1990	A
4904949	Wilson	Feb 1990	A
4905267	Miller et al.	Feb 1990	A
4917344	Prechter et al.	Apr 1990	A
4943781	Wilson et al.	Jul 1990	A
4945478	Merickel et al.	Jul 1990	A
4968915	Wilson et al.	Nov 1990	A
4987309	Klasen et al.	Jan 1991	A
4992744	Fujita et al.	Feb 1991	A
4996496	Kitamura et al.	Feb 1991	A
5006759	Krispel	Apr 1991	A
5010562	Hernandez et al.	Apr 1991	A
5012111	Ueda	Apr 1991	A
5017789	Young et al.	May 1991	A
5017882	Finlan	May 1991	A
5036290	Sonobe et al.	Jul 1991	A
5039057	Prechter et al.	Aug 1991	A
5039867	Nishihara et al.	Aug 1991	A
5046078	Hernandez et al.	Sep 1991	A
5072123	Johnsen	Dec 1991	A
5111042	Sullivan et al.	May 1992	A
5111173	Matsuda et al.	May 1992	A
5117194	Nakanishi et al.	May 1992	A
5117212	Yamamoto et al.	May 1992	A
5117829	Miller et al.	Jun 1992	A
5148032	Hernandez	Sep 1992	A
5166531	Huntzinger	Nov 1992	A
5189687	Bova et al.	Feb 1993	A
5191706	Cosden	Mar 1993	A
5240218	Dye	Aug 1993	A
5260579	Yasuda et al.	Nov 1993	A
5260581	Lesyna et al.	Nov 1993	A
5278533	Kawaguchi	Jan 1994	A
5285166	Hiramoto et al.	Feb 1994	A
5317164	Kurokawa	May 1994	A
5336891	Crewe	Aug 1994	A
5341104	Anton et al.	Aug 1994	A
5349198	Takanaka	Sep 1994	A
5365742	Boffito et al.	Nov 1994	A
5374913	Pissantezky et al.	Dec 1994	A
5382914	Hamm et al.	Jan 1995	A
5401973	McKeown et al.	Mar 1995	A
5405235	Lebre et al.	Apr 1995	A
5434420	McKeown et al.	Jul 1995	A
5440133	Moyers et al.	Aug 1995	A
5451794	McKeown et al.	Sep 1995	A
5461773	Kawaguchi	Oct 1995	A
5463291	Carroll et al.	Oct 1995	A
5464411	Schulte et al.	Nov 1995	A
5492922	Palkowitz	Feb 1996	A
5511549	Legg et al.	Apr 1996	A
5521469	Laisne	May 1996	A
5538942	Koyama et al.	Jul 1996	A
5549616	Schulte et al.	Aug 1996	A
5561697	Takafuji et al.	Oct 1996	A
5585642	Britton et al.	Dec 1996	A
5633747	Nikoonahad	May 1997	A
5635721	Bardi et al.	Jun 1997	A
5668371	Deasy et al.	Sep 1997	A
5672878	Yao	Sep 1997	A
5691679	Ackermann et al.	Nov 1997	A
5726448	Smith et al.	Mar 1998	A
5727554	Kalend et al.	Mar 1998	A
5730745	Schulte et al.	Mar 1998	A
5751781	Brown et al.	May 1998	A
5778047	Mansfield et al.	Jul 1998	A
5783914	Hiramoto et al.	Jul 1998	A
5784431	Kalend et al.	Jul 1998	A
5797924	Schulte et al.	Aug 1998	A
5811944	Sampayan et al.	Sep 1998	A
5818058	Nakanishi et al.	Oct 1998	A
5821705	Caporaso et al.	Oct 1998	A
5825845	Blair et al.	Oct 1998	A
5841237	Alton	Nov 1998	A
5846043	Spath	Dec 1998	A
5851182	Sahadevan	Dec 1998	A
5866912	Slater et al.	Feb 1999	A
5874811	Finlan et al.	Feb 1999	A
5895926	Britton et al.	Apr 1999	A
5920601	Nigg et al.	Jul 1999	A
5929458	Nemezawa et al.	Jul 1999	A
5963615	Egley et al.	Oct 1999	A
5993373	Nonaka et al.	Nov 1999	A
6008499	Hiramoto et al.	Dec 1999	A
6034377	Pu	Mar 2000	A
6057655	Jongen	May 2000	A
6061426	Linders et al.	May 2000	A
6064807	Arai et al.	May 2000	A
6066851	Madono et al.	May 2000	A
6080992	Nonaka et al.	Jun 2000	A
6087670	Hiramoto et al.	Jul 2000	A
6094760	Nonaka et al.	Aug 2000	A
6118848	Reiffel	Sep 2000	A
6140021	Nakasuji et al.	Oct 2000	A
6144875	Schweikard et al.	Nov 2000	A
6158708	Egley et al.	Dec 2000	A
6207952	Kan et al.	Mar 2001	B1
6219403	Nishihara	Apr 2001	B1
6222905	Yoda et al.	Apr 2001	B1
6241671	Ritter et al.	Jun 2001	B1
6246066	Yuehu	Jun 2001	B1
6256591	Yoda et al.	Jul 2001	B1
6265837	Akiyama et al.	Jul 2001	B1
6268610	Pu	Jul 2001	B1
6278239	Caporaso et al.	Aug 2001	B1
6279579	Riaziat et al.	Aug 2001	B1
6307914	Kunieda et al.	Oct 2001	B1
6316776	Hiramoto et al.	Nov 2001	B1
6366021	Meddaugh et al.	Apr 2002	B1
6369585	Yao	Apr 2002	B2
6380545	Yan	Apr 2002	B1
6407505	Bertsche	Jun 2002	B1
6417634	Bergstrom	Jul 2002	B1
6433336	Jongen et al.	Aug 2002	B1
6433349	Akiyama et al.	Aug 2002	B2
6433494	Kulish et al.	Aug 2002	B1
6441569	Janzow	Aug 2002	B1
6443349	Van Der Burg	Sep 2002	B1
6465957	Whitham et al.	Oct 2002	B1
6472834	Hiramoto et al.	Oct 2002	B2
6476403	Dolinskii et al.	Nov 2002	B1
6492922	New	Dec 2002	B1
6493424	Whitham	Dec 2002	B2
6498444	Hanna et al.	Dec 2002	B1
6501981	Schweikard et al.	Dec 2002	B1
6519316	Collins	Feb 2003	B1
6593696	Ding et al.	Jul 2003	B2
6594336	Nishizawa et al.	Jul 2003	B2
6600164	Badura et al.	Jul 2003	B1
6617598	Matsuda	Sep 2003	B1
6621889	Mostafavi	Sep 2003	B1
6639234	Badura et al.	Oct 2003	B1
6646383	Bertsche et al.	Nov 2003	B2
6670618	Hartmann et al.	Dec 2003	B1
6683318	Haberer et al.	Jan 2004	B1
6683426	Kleeven	Jan 2004	B1
6693283	Eickhoff et al.	Feb 2004	B2
6710362	Kraft et al.	Mar 2004	B2
6713773	Lyons et al.	Mar 2004	B1
6713976	Zumoto et al.	Mar 2004	B1
6717162	Jongen	Apr 2004	B1
6736831	Hartmann et al.	May 2004	B1
6745072	Badura et al.	Jun 2004	B1
6769806	Moyers	Aug 2004	B2
6774383	Norimine et al.	Aug 2004	B2
6777689	Nelson	Aug 2004	B2
6777700	Yanagisawa et al.	Aug 2004	B2
6780149	Schulte	Aug 2004	B1
6799068	Hartmann et al.	Sep 2004	B1
6800866	Amemiya et al.	Oct 2004	B2
6803591	Muramatsu et al.	Oct 2004	B2
6814694	Pedroni	Nov 2004	B1
6822244	Beloussov et al.	Nov 2004	B2
6853142	Chistyakov	Feb 2005	B2
6853703	Svatos et al.	Feb 2005	B2
6864770	Nemoto et al.	Mar 2005	B2
6865254	Nafstadius	Mar 2005	B2
6873123	Marchand et al.	Mar 2005	B2
6891177	Kraft et al.	May 2005	B1
6891924	Yoda et al.	May 2005	B1
6894300	Reimoser et al.	May 2005	B2
6897451	Kaercher et al.	May 2005	B2
6914396	Symons et al.	Jul 2005	B1
6936832	Norimine et al.	Aug 2005	B2
6953943	Yanagisawa et al.	Oct 2005	B2
6965116	Wagner et al.	Nov 2005	B1
6969194	Nafstadius	Nov 2005	B1
6979832	Yanagisawa et al.	Dec 2005	B2
6984835	Harada	Jan 2006	B2
6992312	Yanagisawa et al.	Jan 2006	B2
6993112	Hesse	Jan 2006	B2
7008105	Amann et al.	Mar 2006	B2
7011447	Moyers	Mar 2006	B2
7012267	Moriyama et al.	Mar 2006	B2
7014361	Ein-Gal	Mar 2006	B1
7026636	Yanagisawa et al.	Apr 2006	B2
7038403	Mastrangeli et al.	May 2006	B2
7041479	Swartz et al.	May 2006	B2
7045781	Adamec et al.	May 2006	B2
7049613	Yanagisawa et al.	May 2006	B2
7053389	Yanagisawa et al.	May 2006	B2
7054801	Sakamoto et al.	May 2006	B2
7060997	Norimine et al.	Jun 2006	B2
7071479	Yanagisawa et al.	Jul 2006	B2
7073508	Moyers	Jul 2006	B2
7081619	Bashkirov et al.	Jul 2006	B2
7084410	Beloussov et al.	Aug 2006	B2
7091478	Haberer	Aug 2006	B2
7102144	Matsuda et al.	Sep 2006	B2
7122811	Matsuda et al.	Oct 2006	B2
7122966	Norling et al.	Oct 2006	B2
7122978	Nakanishi et al.	Oct 2006	B2
7135678	Wang et al.	Nov 2006	B2
7138771	Bechthold et al.	Nov 2006	B2
7154107	Yanagisawa et al.	Dec 2006	B2
7154108	Tadokoro et al.	Dec 2006	B2
7154991	Earnst et al.	Dec 2006	B2
7162005	Bjorkholm	Jan 2007	B2
7173264	Moriyama et al.	Feb 2007	B2
7173265	Miller et al.	Feb 2007	B2
7173385	Caporasco et al.	Feb 2007	B2
7186991	Kato et al.	Mar 2007	B2
7193227	Hiramoto et al.	Mar 2007	B2
7199382	Rigney et al.	Apr 2007	B2
7208748	Sliski et al.	Apr 2007	B2
7212608	Nagamine et al.	May 2007	B2
7212609	Nagamine et al.	May 2007	B2
7221733	Takai et al.	May 2007	B1
7227161	Matsuda et al.	Jun 2007	B2
7247869	Tadokoro et al.	Jul 2007	B2
7257191	Sommer	Aug 2007	B2
7259529	Tanaka	Aug 2007	B2
7262424	Moriyama et al.	Aug 2007	B2
7262565	Fujisawa	Aug 2007	B2
7274018	Adamec et al.	Sep 2007	B2
7280633	Cheng et al.	Oct 2007	B2
7295649	Johnsen	Nov 2007	B2
7297967	Yanagisawa et al.	Nov 2007	B2
7301162	Matsuda et al.	Nov 2007	B2
7307264	Brusasco et al.	Dec 2007	B2
7318805	Schweikard et al.	Jan 2008	B2
7319231	Moriyama et al.	Jan 2008	B2
7319336	Baur et al.	Jan 2008	B2
7331713	Moyers	Feb 2008	B2
7332880	Ina et al.	Feb 2008	B2
7345291	Kats	Mar 2008	B2
7345292	Moriyama et al.	Mar 2008	B2
7348557	Armit	Mar 2008	B2
7348579	Pedroni	Mar 2008	B2
7351988	Naumann et al.	Apr 2008	B2
7355189	Yanagisawa et al.	Apr 2008	B2
7368740	Beloussov et al.	May 2008	B2
7372053	Yamashita et al.	May 2008	B2
7378672	Harada	May 2008	B2
7381979	Yamashita et al.	Jun 2008	B2
7397054	Natori et al.	Jul 2008	B2
7397901	Johnsen	Jul 2008	B1
7398309	Baumann et al.	Jul 2008	B2
7402822	Guertin et al.	Jul 2008	B2
7402823	Guertin et al.	Jul 2008	B2
7402824	Guertin et al.	Jul 2008	B2
7402963	Sliski	Jul 2008	B2
7405407	Hiramoto et al.	Jul 2008	B2
7425717	Matsuda et al.	Sep 2008	B2
7432516	Peggs et al.	Oct 2008	B2
7439528	Nishiuchi et al.	Oct 2008	B2
7446328	Rigney et al.	Nov 2008	B2
7446490	Jongen et al.	Nov 2008	B2
7449701	Fujimaki et al.	Nov 2008	B2
7453076	Welch et al.	Nov 2008	B2
7465944	Ueno et al.	Dec 2008	B2
7466085	Nutt	Dec 2008	B2
7468506	Rogers et al.	Dec 2008	B2
7473913	Hermann et al.	Jan 2009	B2
7476867	Fritsch et al.	Jan 2009	B2
7476883	Nutt	Jan 2009	B2
7482606	Groezinger et al.	Jan 2009	B2
7492556	Atkins et al.	Feb 2009	B2
7507975	Mohr	Mar 2009	B2
7525104	Harada	Apr 2009	B2
7541905	Antaya	Jun 2009	B2
7547901	Guertin et al.	Jun 2009	B2
7554096	Ward et al.	Jun 2009	B2
7554097	Ward et al.	Jun 2009	B2
7555103	Johnsen	Jun 2009	B2
7557358	Ward et al.	Jul 2009	B2
7557359	Ward et al.	Jul 2009	B2
7557360	Ward et al.	Jul 2009	B2
7557361	Ward et al.	Jul 2009	B2
7560715	Pedroni	Jul 2009	B2
7560717	Matsuda et al.	Jul 2009	B2
7567694	Lu et al.	Jul 2009	B2
7574251	Lu et al.	Aug 2009	B2
7576499	Caporaso et al.	Aug 2009	B2
7579603	Birgy et al.	Aug 2009	B2
7579610	Grozinger et al.	Aug 2009	B2
7582866	Furuhashi et al.	Sep 2009	B2
7582885	Katagiri et al.	Sep 2009	B2
7582886	Trbojevic	Sep 2009	B2
7586112	Chiba et al.	Sep 2009	B2
7598497	Yamamoto et al.	Oct 2009	B2
7609009	Tanaka et al.	Oct 2009	B2
7609809	Kapatoes et al.	Oct 2009	B2
7609811	Siljamaki et al.	Oct 2009	B1
7615942	Sanders et al.	Nov 2009	B2
7626347	Sliski	Dec 2009	B2
7629598	Harada	Dec 2009	B2
7639853	Olivera et al.	Dec 2009	B2
7639854	Schnarr et al.	Dec 2009	B2
7643661	Ruchala et al.	Jan 2010	B2
7656258	Antaya et al.	Feb 2010	B1
7659521	Pedroni	Feb 2010	B2
7659528	Uematsu	Feb 2010	B2
7668291	Nord et al.	Feb 2010	B2
7672429	Urano et al.	Mar 2010	B2
7679073	Urano et al.	Mar 2010	B2
7682078	Rietzel	Mar 2010	B2
7692166	Muraki et al.	Apr 2010	B2
7692168	Moriyama et al.	Apr 2010	B2
7696499	Miller et al.	Apr 2010	B2
7696847	Antaya	Apr 2010	B2
7701677	Schultz et al.	Apr 2010	B2
7709818	Matsuda et al.	May 2010	B2
7710051	Caporaso et al.	May 2010	B2
7718982	Sliski et al.	May 2010	B2
7728311	Gall	Jun 2010	B2
7746978	Cheng et al.	Jun 2010	B2
7755305	Umezawa et al.	Jul 2010	B2
7759642	Nir	Jul 2010	B2
7763867	Birgy et al.	Jul 2010	B2
7767988	Kaiser et al.	Aug 2010	B2
7770231	Prater et al.	Aug 2010	B2
7772577	Saito et al.	Aug 2010	B2
7773723	Nord et al.	Aug 2010	B2
7773788	Lu et al.	Aug 2010	B2
7778488	Nord et al.	Aug 2010	B2
7783010	Clayton	Aug 2010	B2
7784127	Kuro et al.	Aug 2010	B2
7786451	Ward et al.	Aug 2010	B2
7786452	Ward et al.	Aug 2010	B2
7789560	Moyers	Sep 2010	B2
7791051	Beloussov et al.	Sep 2010	B2
7796731	Nord et al.	Sep 2010	B2
7801269	Cravens et al.	Sep 2010	B2
7801270	Nord et al.	Sep 2010	B2
7801988	Baumann et al.	Sep 2010	B2
7807982	Nishiuchi et al.	Oct 2010	B2
7809107	Nord et al.	Oct 2010	B2
7812319	Diehl et al.	Oct 2010	B2
7812326	Grozinger et al.	Oct 2010	B2
7816657	Hansmann et al.	Oct 2010	B2
7817778	Nord et al.	Oct 2010	B2
7817836	Chao et al.	Oct 2010	B2
7834334	Grozinger et al.	Nov 2010	B2
7834336	Boeh et al.	Nov 2010	B2
7835494	Nord et al.	Nov 2010	B2
7835502	Spence et al.	Nov 2010	B2
7839972	Ruchala et al.	Nov 2010	B2
7839973	Nord et al.	Nov 2010	B2
7848488	Mansfield	Dec 2010	B2
7857756	Warren et al.	Dec 2010	B2
7860216	Jongen et al.	Dec 2010	B2
7860550	Saracen et al.	Dec 2010	B2
7868301	Diehl	Jan 2011	B2
7875861	Huttenberger et al.	Jan 2011	B2
7875868	Moriyama et al.	Jan 2011	B2
7881431	Aoi et al.	Feb 2011	B2
7894574	Nord et al.	Feb 2011	B1
7906769	Blasche et al.	Mar 2011	B2
7914734	Livingston	Mar 2011	B2
7919765	Timmer	Apr 2011	B2
7920040	Antaya et al.	Apr 2011	B2
7920675	Lomax et al.	Apr 2011	B2
7928415	Bert et al.	Apr 2011	B2
7934869	Ivanov et al.	May 2011	B2
7940881	Jongen et al.	May 2011	B2
7943913	Balakin	May 2011	B2
7947969	Pu	May 2011	B2
7949096	Cheng et al.	May 2011	B2
7950587	Henson et al.	May 2011	B2
7960710	Kruip et al.	Jun 2011	B2
7961844	Takeda et al.	Jun 2011	B2
7977648	Westerly et al.	Jul 2011	B2
7977656	Fujimaki et al.	Jul 2011	B2
7982198	Nishiuchi et al.	Jul 2011	B2
7982416	Tanaka et al.	Jul 2011	B2
7984715	Moyers	Jul 2011	B2
7986768	Nord et al.	Jul 2011	B2
7987053	Schaffner	Jul 2011	B2
7989785	Emhofer et al.	Aug 2011	B2
7990524	Jureller et al.	Aug 2011	B2
7997553	Sloan et al.	Aug 2011	B2
8002466	Von Neubeck et al.	Aug 2011	B2
8003964	Stark et al.	Aug 2011	B2
8009803	Nord et al.	Aug 2011	B2
8009804	Siljamaki et al.	Aug 2011	B2
8039822	Rietzel	Oct 2011	B2
8041006	Boyden et al.	Oct 2011	B2
8044364	Yamamoto	Oct 2011	B2
8049187	Tachikawa	Nov 2011	B2
8053508	Korkut et al.	Nov 2011	B2
8053739	Rietzel	Nov 2011	B2
8053745	Moore	Nov 2011	B2
8053746	Timmer et al.	Nov 2011	B2
8067748	Balakin	Nov 2011	B2
8069675	Radovinsky et al.	Dec 2011	B2
8071966	Kaiser et al.	Dec 2011	B2
8080801	Safai	Dec 2011	B2
8085899	Nord et al.	Dec 2011	B2
8089054	Balakin	Jan 2012	B2
8093564	Balakin	Jan 2012	B2
8093568	Mackie et al.	Jan 2012	B2
8111125	Antaya et al.	Feb 2012	B2
8129699	Balakin	Mar 2012	B2
8144832	Balakin	Mar 2012	B2
8173981	Trbojevic	May 2012	B2
8188688	Balakin	May 2012	B2
8198607	Balakin	Jun 2012	B2
8222613	Tajiri et al.	Jul 2012	B2
8227768	Smick et al.	Jul 2012	B2
8232536	Harada	Jul 2012	B2
8288742	Balakin	Oct 2012	B2
8291717	Radovinsky et al.	Oct 2012	B2
8294127	Tachibana	Oct 2012	B2
8304725	Komuro et al.	Nov 2012	B2
8304750	Preikszas et al.	Nov 2012	B2
8309941	Balakin	Nov 2012	B2
8330132	Guertin et al.	Dec 2012	B2
8334520	Otaka et al.	Dec 2012	B2
8335397	Takane et al.	Dec 2012	B2
8344340	Gall et al.	Jan 2013	B2
8350214	Otaki et al.	Jan 2013	B2
8368038	Balakin	Feb 2013	B2
8368043	Havelange et al.	Feb 2013	B2
8373143	Balakin	Feb 2013	B2
8373145	Balakin	Feb 2013	B2
8378299	Frosien	Feb 2013	B2
8378321	Balakin	Feb 2013	B2
8382943	Clark	Feb 2013	B2
8389949	Harada et al.	Mar 2013	B2
8399866	Balakin	Mar 2013	B2
8405042	Honda et al.	Mar 2013	B2
8405056	Amaldi et al.	Mar 2013	B2
8415643	Balakin	Apr 2013	B2
8416918	Nord et al.	Apr 2013	B2
8421041	Balakin	Apr 2013	B2
8426833	Trbojevic	Apr 2013	B2
8436323	Iseki et al.	May 2013	B2
8440987	Stephani et al.	May 2013	B2
8445872	Behrens et al.	May 2013	B2
8466441	Iwata et al.	Jun 2013	B2
8472583	Star-Lack et al.	Jun 2013	B2
8483357	Siljamaki et al.	Jul 2013	B2
8487278	Balakin	Jul 2013	B2
8552406	Phaneuf et al.	Oct 2013	B2
8552408	Hanawa et al.	Oct 2013	B2
8569717	Balakin	Oct 2013	B2
8581215	Balakin	Nov 2013	B2
8581523	Gall et al.	Nov 2013	B2
8581525	Antaya et al.	Nov 2013	B2
8653314	Pelati et al.	Feb 2014	B2
8653473	Yajima	Feb 2014	B2
20020172317	Maksimchuk et al.	Nov 2002	A1
20030048080	Amemiya et al.	Mar 2003	A1
20030125622	Schweikard et al.	Jul 2003	A1
20030136924	Kraft et al.	Jul 2003	A1
20030152197	Moyers	Aug 2003	A1
20030163015	Yanagisawa et al.	Aug 2003	A1
20030183779	Norimine et al.	Oct 2003	A1
20030234369	Glukhoy	Dec 2003	A1
20040000650	Yanagisawa et al.	Jan 2004	A1
20040017888	Seppi et al.	Jan 2004	A1
20040056212	Yanagisawa et al.	Mar 2004	A1
20040061077	Muramatsu et al.	Apr 2004	A1
20040061078	Muramatsu et al.	Apr 2004	A1
20040085023	Chistyakov	May 2004	A1
20040098445	Baumann et al.	May 2004	A1
20040111134	Muramatsu et al.	Jun 2004	A1
20040118081	Reimoser et al.	Jun 2004	A1
20040149934	Yanagisawa et al.	Aug 2004	A1
20040159795	Kaercher et al.	Aug 2004	A1
20040173763	Moriyama et al.	Sep 2004	A1
20040174958	Moriyama et al.	Sep 2004	A1
20040183033	Moriyama et al.	Sep 2004	A1
20040183035	Yanagisawa et al.	Sep 2004	A1
20040200982	Moriyama et al.	Oct 2004	A1
20040200983	Fujimaki et al.	Oct 2004	A1
20040213381	Harada	Oct 2004	A1
20040227104	Matsuda et al.	Nov 2004	A1
20040232356	Norimine et al.	Nov 2004	A1
20040240626	Moyers	Dec 2004	A1
20050058245	Ein-Gal	Mar 2005	A1
20050089141	Brown	Apr 2005	A1
20050161618	Pedroni	Jul 2005	A1
20050184686	Caporaso et al.	Aug 2005	A1
20050228255	Saracen et al.	Oct 2005	A1
20050234327	Saracen et al.	Oct 2005	A1
20050247890	Norimine et al.	Nov 2005	A1
20060017015	Sliski et al.	Jan 2006	A1
20060067468	Rietzel	Mar 2006	A1
20060126792	Li	Jun 2006	A1
20060145088	Ma	Jul 2006	A1
20060175991	Fujisawa	Aug 2006	A1
20060273264	Nakayama et al.	Dec 2006	A1
20060284562	Hruby et al.	Dec 2006	A1
20070001128	Sliski et al.	Jan 2007	A1
20070013273	Albert et al.	Jan 2007	A1
20070014654	Haverfield et al.	Jan 2007	A1
20070023699	Yamashita et al.	Feb 2007	A1
20070029510	Hermann et al.	Feb 2007	A1
20070051904	Kaiser et al.	Mar 2007	A1
20070061937	Curle	Mar 2007	A1
20070092812	Caporaso et al.	Apr 2007	A1
20070114945	Mattaboni et al.	May 2007	A1
20070145916	Caporaso et al.	Jun 2007	A1
20070171015	Antaya	Jul 2007	A1
20070181519	Khoshnevis	Aug 2007	A1
20070252093	Fujimaki et al.	Nov 2007	A1
20070284548	Kaiser et al.	Dec 2007	A1
20080067452	Moriyama et al.	Mar 2008	A1
20080093567	Gall	Apr 2008	A1
20080218102	Sliski	Sep 2008	A1
20090096179	Stark et al.	Apr 2009	A1
20090140671	O'Neal et al.	Jun 2009	A1
20090140672	Gall et al.	Jun 2009	A1
20090200483	Gall et al.	Aug 2009	A1
20100045213	Sliski et al.	Feb 2010	A1
20100230617	Gall	Sep 2010	A1
20100308235	Sliski	Dec 2010	A1
20110240874	Iwata	Oct 2011	A1
20110299919	Stark	Dec 2011	A1
20120081041	Cheung et al.	Apr 2012	A1
20130053616	Gall	Feb 2013	A1
20130127375	Sliski	May 2013	A1
20130131424	Sliski	May 2013	A1
20130237425	Leigh et al.	Sep 2013	A1
20140028220	Bromberg et al.	Jan 2014	A1
20140042934	Tsutsui	Feb 2014	A1
20140097920	Goldie et al.	Apr 2014	A1
20150099917	Bula et al.	Apr 2015	A1
20150099918	Takayanagi et al.	Apr 2015	A1

Foreign Referenced Citations (141)

Number	Date	Country
2629333	May 2007	CA
1377521	Oct 2002	CN
1537657	Oct 2004	CN
1816243	Aug 2006	CN
101932361	Dec 2010	CN
101933405	Dec 2010	CN
101933406	Dec 2010	CN
101061759	May 2011	CN
2753397	Jun 1978	DE
31 48 100	Jun 1983	DE
35 30 446	Aug 1984	DE
41 01 094 CI	May 1992	DE
4411171	Oct 1995	DE
0 194 728	Sep 1986	EP
0 277 521	Aug 1988	EP
0 208 163	Jan 1989	EP
0 222 786	Jul 1990	EP
0 221 987	Jan 1991	EP
0 499 253	Aug 1992	EP
0 306 966	Apr 1995	EP
0 388 123	May 1995	EP
0 465 597	May 1997	EP
0 911 064	Jun 1998	EP
0 864 337	Sep 1998	EP
0 776 595	Dec 1998	EP
1 069 809	Jan 2001	EP
1 153 398	Apr 2001	EP
1 294 445	Mar 2003	EP
1 348 465	Oct 2003	EP
1 358 908	Nov 2003	EP
1 371 390	Dec 2003	EP
1 402 923	Mar 2004	EP
1 430 932	Jun 2004	EP
1 454 653	Sep 2004	EP
1 454 654	Sep 2004	EP
1 454 655	Sep 2004	EP
1 454 656	Sep 2004	EP
1 454 657	Sep 2004	EP
1 477 206	Nov 2004	EP
1 738 798	Jan 2007	EP
1 826 778	Aug 2007	EP
1 949 404	Jul 2008	EP
2183753	Jul 2008	EP
2394498	Feb 2010	EP
2232961	Sep 2010	EP
2232962	Sep 2010	EP
2227295	May 2011	EP
1 605 742	Jun 2011	EP
2363170	Sep 2011	EP
2363171	Sep 2011	EP
2 560 421	Aug 1985	FR
2911843	Aug 2008	FR
0 957 342	May 1964	GB
2 015 821	Sep 1979	GB
2 361 523	Oct 2001	GB
43-23267	Oct 1968	JP
U48-108098	Dec 1973	JP
57-162527	Oct 1982	JP
58-141000	Aug 1983	JP
61-80800	Apr 1986	JP
61-225798	Oct 1986	JP
62-150804	Jul 1987	JP
62-186500	Aug 1987	JP
10-071213	Mar 1988	JP
63-149344	Jun 1988	JP
63-218200	Sep 1988	JP
63-226899	Sep 1988	JP
64-89621	Apr 1989	JP
01-276797	Nov 1989	JP
01-302700	Dec 1989	JP
4-94198	Mar 1992	JP
04-128717	Apr 1992	JP
04-129768	Apr 1992	JP
04-273409	Sep 1992	JP
04-337300	Nov 1992	JP
05-341352	Dec 1993	JP
06-233831	Aug 1994	JP
06-036893	Oct 1994	JP
07-260939	Oct 1995	JP
07-263196	Oct 1995	JP
08-173890	Jul 1996	JP
08-264298	Oct 1996	JP
09-162585	Jun 1997	JP
11-47287	Feb 1999	JP
11-102800	Apr 1999	JP
11-243295	Sep 1999	JP
2000-243309	Sep 2000	JP
2000-294399	Oct 2000	JP
2001-6900	Jan 2001	JP
2001-009050	Jan 2001	JP
2001-129103	May 2001	JP
2001-346893	Dec 2001	JP
2002-164686	Jun 2002	JP
A2003-504628	Feb 2003	JP
2003-517755	May 2003	JP
2004-031115	Jan 2004	JP
2005-526578	Sep 2005	JP
2006-032282	Feb 2006	JP
05-046928	Mar 2008	JP
2008-507826	Mar 2008	JP
2009-515671	Apr 2009	JP
2009-516905	Apr 2009	JP
2010-536130	Nov 2010	JP
2011-505191	Feb 2011	JP
2011-505670	Feb 2011	JP
2011-507151	Mar 2011	JP
300137	Nov 1969	SU
569 635	Aug 1977	SU
200930160	Jul 2009	TW
200934682	Aug 2009	TW
200939908	Sep 2009	TW
200940120	Oct 2009	TW
WO 8607229	Dec 1986	WO
WO 9012413	Oct 1990	WO
WO 9203028	Feb 1992	WO
WO 9302536	Feb 1993	WO
WO 9817342	Apr 1998	WO
WO 9939385	Aug 1999	WO
WO 0040064	Jul 2000	WO
WO 0049624	Aug 2000	WO
WO 0126230	Apr 2001	WO
WO 0126569	Apr 2001	WO
WO 0207817	Jan 2002	WO
WO 03039212	May 2003	WO
WO 03092812	Nov 2003	WO
WO 2004026401	Apr 2004	WO
WO 2004101070	Nov 2004	WO
WO 2006-012467	Feb 2006	WO
WO 2007061937	May 2007	WO
WO 2007084701	Jul 2007	WO
WO 2007130164	Nov 2007	WO
WO 2007145906	Dec 2007	WO
WO 2008030911	Mar 2008	WO
WO 2008081480	Oct 2008	WO
WO 2009048745	Apr 2009	WO
WO 2009070173	Jun 2009	WO
WO 2009070588	Jun 2009	WO
WO 2009073480	Jun 2009	WO
WO2014018706	Jan 2014	WO
WO2014018876	Jan 2014	WO
WO 2014052721	Apr 2014	WO

Non-Patent Literature Citations (243)

Entry
US 8,581,524, 11/2013, O'Neal et al. (withdrawn)
U.S. Appl. No. 61/676,377, filed Jul. 27, 2012, including the USPTO electronic file for U.S. Appl. No. 61/676,377.
U.S. Appl. No. 13/949,459, filed Jul. 24, 2013, including the USPTO electronic file for U.S. Appl. No. 13/949,459.
U.S. Appl. No. 13/830,792, filed Mar. 14, 2013, including the USPTO electronic file for U.S. Appl. No. 13/830,792.
European Communication from European application No. 13774886.9 issued on Jun. 12, 2015 (2 pages).
Response to European Communication mailed Jun. 12, 2015 in European application No. 13774886.9 filed on Jun. 23, 2015 (17 pages).
“Beam Delivery and Properties,” Journal of the ICRU, 2007, 7(2):20 pages.
“510(k) Summary: Ion Beam Applications S.A.”, FDA, Jul. 12, 2001, 5 pages.
“510(k) Summary: Optivus Proton Beam Therapy System”, Jul. 21, 2000, 5 pages.
“An Accelerated Collaboration Meets with Beaming Success,” Lawrence Livermore National Laboratory, Apr. 12, 2006, S&TR, Livermore, California, pp. 1-3, http://www.llnl.gov/str/April06/Caporaso.html.
“CPAC Highlights Its Proton Therapy Program at ESTRO Annual Meeting”, TomoTherapy Incorporated, Sep. 18, 2008, Madison, Wisconsin, pp. 1-2.
“Indiana's mega-million proton therapy cancer center welcomes its first patients” [online] Press release, Health & Medicine Week, 2004, retrieved from NewsRx.com, Mar. 1, 2004, pp. 119-120.
“LLNL, UC Davis Team Up to Fight Cancer,”Lawrence Livermore National Laboratory, Apr. 28, 2006, SF-06-04-02, Livermore, California, pp. 1-4.
“Patent Assignee Search Paul Scherrer Institute,” Library Services at Fish & Richardson P.C., Mar. 20, 2007, 40 pages.
“Patent Prior Art Search for ‘Proton Therapy System’,” Library Services at Fish & Richardson P.C., Mar. 20, 2007, 46 pages.
“Superconducting Cyclotron Contract” awarded by Paul Scherrer Institute (PSI), Villigen, Switzerland, http://www.accel.de/News/superconducting—cyclotron—contract.htm, Jan. 2009, 1 page.
“The Davis 76-Inch Isochronous Cyclotron”, Beam on: Crocker Nuclear Laboratory, University of California, 2009, 1 page.
“The K100 Neutron-therapy Cyclotron,” National Superconducting Cyclotron Laboratory at Michigan State University (NSCL), retrieved from: http://www.nscl.msu.edu/tech/accelerators/k100, Feb. 2005, 1 page.
“The K250 Proton therapy Cyclotron,” National Superconducting Cyclotron Laboratory at Michigan State University (NSCL), retrieved from: http://www.nscl.msu.edu/tech/accelerators/k250.html , Feb. 2005, 2 pages.
“The K250 Proton-therapy Cyclotron Photo Illustration,” National Superconducting Cyclotron Laboratory at Michigan State University (NSCL), retrieved from: http://www.nscl.msu.edu/media/image/experimental-equipment-technology/250.html, Feb. 2005, 1 page.
18th Japan Conference on Radiation and Radioisotopes [Japanese], Nov. 25-27, 1987, 9 pages.
Abrosimov et al., “1000MeV Proton Beam Therapy facility at Petersburg Nuclear Physics Institute Synchrocyclotron,” Medical Radiology (Moscow) 32, 10 (1987) revised in Journal of Physics, Conference Series 41, 2006, pp. 424-432, Institute of Physics Publishing Limited.
Abrosimov et al., “Neutron Time-of-flight Spectrometer Gneis at the Gatchina 1 GeV Protron Syncrhocyclotron”, Mar. 9, 1985 and revised form Jul. 31, 1985, Lemingrad Nuclear Physics Institute, Gatchina, 188350, USSR (15 pages).
Adachi et al., “A 150MeV FFAG Synchrotron with “Return-Yoke Free” Magent,” Proceedings of the 2001 Particle Accelerator Conference, Chicago, 2001, 3 pages.
Ageyev et al., “The IHEP Accelerating and Storage Complex (UNK) Status Report,” 11th International Conference on High-Energy Accelerators, 1980, pp. 60-70.
Agosteo et al., “Maze Design of a gantry room for proton therapy, ”Nuclear Instruments & Methods in Physics Research, 1996, Section A, 382, pp. 573-582.
Alexeev et al., “R4 Design of Superconducting Magents for Proton Synchrotrons,” Proceedings of the Fifth International Cryogenic Engineering Conference, 1974, pp. 531-533.
Allardyce et al., “Performance and Prospects of the Reconstructed CERN 600 MeV Synchrocyclotron,” IEEE Transactions on Nuclear Science USA, Jun. 1977, ns-24:(3)1631-1633.
Alonso, “Magnetically Scanned Ion Beams for Radiation Therapy,” Accelerator & Fusion Research Division, Lawrence Berkeley Laboratory, Berkeley, CA, Oct. 1988, 13 pages.
Amaldi et al., “The Italian project for a hadrontherapy centre” Nuclear Instruments and Methods in Physics Research A, 1995, 360, pp. 297-301.
Amaldi, “Overview of the world landscape of Hadrontherapy and the projects of the TERA foundation,” Physica Medica, An International journal Devoted to the Applications of Physics to Medicine and Biology, Jul. 1998, vol. XIV, Supplement 1, 6th Workshop on Heavy Charged Particles in Biology and Medicine, Instituto Scientific Europeo (ISE), Sep. 29-Oct. 1, 1977, Baveno, pp. 76-85.
Anferov et al., “Status of the Midwest Proton Radiotherapy Institute,” Proceedings of the 2003 Particle Accelerator Conference, 2003, pp. 699-701.
Anferov et al., “The Indiana University Midwest Proton Radiation Institute,” Proceedings of the 2001 Particle Accelerator Conference, 2001, Chicago, pp. 645-647.
Appun, “Various problems of magnet fabrication for high-energy accelerators.” Journal for All Engineers Interested in the Nuclear Field, 1967, pp. 10-16 (1967) [Lang.: German], English bibliographic information (http://www.osti.gov/energycitations/product.biblio.jsp?osti—id=4442292).
Arduini et al. “Physical specifications of clinical proton beams from a synchrotron,” Med. Phys, Jun. 1996, 23 (6): 939-951.
Badano et al., “Proton-Ion Medical Machine Study (PIMMS) Part I,” PIMMS, Jan. 1999, 238 pages.
Beeckman et al., “Preliminary design of a reduced cost proton therapy facility using a compact, high field isochronous cyclotron,” Nuclear Instruments and Methods in Physics Research B56/57, 1991, pp. 1201-1204.
Bellomo et al., “The Superconducting Cyclotron Program at Michigan State University,” Bulletin of the American Physical Society, Sep. 1980, 25(7):767.
Benedikt and Carli, “Matching to Gantries for Medical Synchrotrons” IEEE Proceedings of the 1997 Particle Accelerator Conference, 1997, pp. 1379-1381.
Bieth et al., “A Very Compact Protontherapy Facility Based on an Extensive Use of High Temperature Superconductors (HTS)” Cyclotrons and their Applications 1998, Proceedings of the Fifteenth International Conference on Cyclotrons and their Applications, Caen, Jun. 14-19, 1998, pp. 669-672.
Bigham, “Magnetic Trim Rods for Superconducting Cyclotrons,” Nuclear Instruments and Methods (North-Holland Publishing Co.), 1975, 141:223-228.
Bimbot, “First Studies of the External Beam from the Orsay S.C. 200 MeV,” Institut de Physique Nucleaire, BP 1, Orsay, France, IEEE, 1979, pp. 1923-1926.
Blackmore et al., “Operation of the Triumf Proton Therapy Facility,” IEEE Proceedings of the 1997 Particle Accelerator Conference, May 12-16, 19973:3831-3833.
Bloch, “The Midwest Proton Therapy Center,” Application of Accelerators in Research and Industry, Proceedings of the Fourteenth Int'l. Conf., Part Two, Nov. 1996, pp. 1253-1255.
Blosser et al., “Problems and Accomplishments of Superconducting Cyclotrons,” Proceedings of the 14th International Conference, Cyclotrons and Their Applications, Oct. 1995, pp. 674-684.
Blosser et al., “Superconducting Cyclotrons”, Seventh International Conference on Cyclotrons and their Applications, Aug. 19-22, 1975, pp. 584-594.
Blosser et al., “Progress toward an experiment to study the effect of RF grounding in an internal ion source on axial oscillations of the beam in a cyclotron,” National Superconducting Cyclotron Laboratory, Michigan State University, Report MSUCL-760, CP600, Cyclotrons and their Applications 2011, Sixteenth International Conference, 2001, pp. 274-276.
Blosser et al., “A Compact Superconducting Cyclotron for the Production of High Intensity Protons,” Proceedings of the 1997 Particle Accelerator Conference, May 12-16, 1997, 1:1054-1056.
Blosser et al., “Advances in Superconducting Cyclotrons at Michigan State University,” Proceedings of the 11th International Conference on Cyclotrons and their Applications, Oct. 1986, pp. 157-167, Tokyo.
Blosser et al., “Characteristics of a 400 (Q2/A) MeV Super-Conducting Heavy-Ion Cyclotron,” Bulletin of the American Physical Society, Oct. 1974, p. 1026.
Blosser et al., “Medical Accelerator Projects at Michigan State Univ.” IEEE Proceedings of the 1989 Particle Accelerator Conference, Mar. 20-23, 1989, 2:742-746.
Blosser et al., “Superconducting Cyclotron for Medical Application”, IEEE Transactions on Magnetics, Mar. 1989, 25(2): 1746-1754.
Blosser, “Application of Superconductivity in Cyclotron Construction,” Ninth International Conference on Cyclotrons and their Applications, Sep. 1981, pp. 147-157.
Blosser, “Applications of Superconducting Cyclotrons,” Twelfth International Conference on Cyclotrons and Their Applications, May 8-12, 1989, pp. 137-144.
Blosser, “Future Cyclotrons,” AIP, The Sixth International Cyclotron Conference, 1972, pp. 16-32.
Blosser, “Medical Cyclotrons,” Physics Today, Special Issue Physical Review Centenary, Oct. 1993, pp. 70-73.
Blosser, “Preliminary Design Study Exploring Building Features Required for a Proton Therapy Facility for the Ontario Cancer Institute”, Mar. 1991, MSUCL-760a, 53 pages.
Blosser, “Progress on the Coupled Superconducting Cyclotron Project,” Bulletin of the American Physical Society, Apr. 1981, 26(4):558.
Blosser, “Synchrocyclotron Improvement Programs,” IEEE Transactions on Nuclear Science USA, Jun. 1969, 16(3):Part I, pp. 405-414.
Blosser, “The Michigan State University Superconducting Cyclotron Program,” Nuclear Science, Apr. 1979, NS-26(2):2040-2047.
Blosser, H., Present and Future Superconducting Cyclotrons, Bulletin of the American Physical Society, Feb. 1987, 32(2):171 Particle Accelerator Conference, Washington, D.C.
Blosser, H.G., “Superconducting Cyclotrons at Michigan State University”, Nuclear Instruments & Methods in Physics Research, 1987,vol. B 24/25, part II, pp. 752-756.
Botha et al., “A New Multidisciplinary Separated-Sector Cyclotron Facility,” IEEE Transactions on Nuclear Science, 1977, NS-24(3):1118-1120.
Chichili et al., “Fabrication of Nb3Sn Shell-Type Coils with Pre-Preg Ceramic Insulation,” American Institute of Physics Conference Proceedings, AIP USA, No. 711, (XP-002436709, ISSN: 0094-243X), 2004, pp. 450-457.
Chong et al., Radiology Clinic North American 7, 3319, 1969, 27 pages.
Chu et al., “Performance Specifications for Proton Medical Facility,” Lawrence Berkeley Laboratory, University of California, Mar. 1993, 128 pages.
Chu et al., “Instrumentation for Treatment of Cancer Using Proton and Light-ion Beams,” Review of Scientific Instruments, Aug. 1993, 64 (8):2055-2122.
Chu, “Instrumentation in Medical Systems,” Accelerator and Fusion Research Division, Lawrence Berkeley Laboratory, University of California, Berkeley, CA, May 1995, 9 pages.
Cole et al., “Design and Application of a Proton Therapy Accelerator,” Fermi National Accelerator Laboratory, IEEE, 1985, 5 pages.
Collins, et al., “The Indiana University Proton Therapy System,” Proceedings of EPAC 2006, Edinburgh, Scotland, 2006, 3 pages.
Conradi et al., “Proposed New Facilities for Proton Therapy at iThemba Labs,” Proceedings of EPAC, 2002, pp. 560-562.
C/E Source of Ions for Use in Sychro-Cyclotrons Search, Jan. 31, 2005, 9 pages.
Source Search “Cites of U.S. and Foreign Patents/Published applications in the name of Mitsubishi Denki Kabushiki Kaisha and Containing the Keywords (Proton and Synchrocyclotron),” Jan. 2005, 8 pages.
Cosgrove et al., “Microdosimetric Studies on the Orsay Proton Synchrocyclotron at 73 and 200 MeV,” Radiation Protection Dosimetry, 1997, 70(1-4):493-496.
Coupland, “High-field (5 T) pulsed superconducting dipole magnet,” Proceedings of the Institution of Electrical Engineers, Jul. 1974, 121(7):771-778.
Coutrakon et al. “Proton Synchrotrons for Cancer Therapy,” Application of Accelerators in Research and Industry—Sixteenth International Conf., American Institute of Physics, Nov. 1-5, 2000, vol. 576, pp. 861-864.
Coutrakon et al., “A prototype beam delivery system for the proton medical accelerator at Loma Linda,” Medical Physics, Nov./Dec. 1991, 18(6):1093-1099.
Cuttone, “Applications of a Particle Accelerators in Medical Physics,” Istituto Nazionale di Fisica Nucleare-Laboratori Nazionali del Sud, V.S. Sofia, 44 Cantania, Italy, Jan. 2010, 17 pages.
Dahl P, “Superconducting Magnet System,” American Institute of Physics, AIP Conference Proceedings, 1987-1988, 2: 1329-1376.
Dialog Search, Jan. 31, 2005, 17 pages.
Dugan et al., “Tevatron Status” IEEE, Particle Accelerator Conference, Accelerator Science & Technology, 1989, pp. 426-430.
Eickhoff et al., “The Proposed Accelerator Facility for Light Ion Cancer Therapy in Heidelberg,” Proceedings of the 1999 Particle Accelerator Conference, New York, 1999, pp. 2513-2515.
Enchevich et al., “Minimizing Phase Losses in the 680 MeV Synchrocyclotron by Correcting the Accelerating Voltage Amplitude,” Atomnaya Energiya, 1969, 26:(3):315-316.
Endo et al., “Compact Proton and Carbon Ion Synchrotrons for Radiation Therapy,” Proceedings of EPAC 2002, Paris France, 2002, pp. 2733-2735.
Flanz et al., “Treating Patients with the NPTC Accelerator Based Proton Treatment Facility,” Proceedings of the 2003 Particle Accelerator Conference, 2003, pp. 690-693.
Flanz et al., “Large Medical Gantries,” Particle Accelerator Conference, Massachusetts General Hospital, 1995, pp. 1-5.
Flanz et al., “Operation of a Cyclotron Based Proton Therapy Facility”, Massachusetts General Hospital, Boston, MA 02114, pp. 1-4, retrieved from Internet in 2009.
Flanz et al., “The Northeast Proton Therapy Center at Massachusetts General Hospital,” Fifth Workshop on Heavy Charge Particles in Biology and Medicine, GSI, Darmstadt, Aug. 1995, 11 pages.
Flood and Frazier, “The Wide-Band Driven RF System for the Berkeley 88-Inch Cyclotron,” American Institute of Physics, Conference Proceedings., No. 9, 1972, 459-466.
Foster and Kashikhin, “Superconducting Superferric Dipole Magent with Cold Iron Core for the VLHC,” IEEE Transactions on Applied Superconductivity, Mar. 2002, 12(1):111-115.
Friesel et al., “Design and Construction Progress on the IUCF Midwest Proton Radiation Institute,” Proceedings of EPAC 2002, 2002, pp. 2736-2738.
Fukumoto et al., “A Proton Therapy Facility Plan” Cyclotrons and their Applications, Proceedings of the 13th International Conference, Vancouver, Canada, Jul. 6-10, 1992, pp. 258-261.
Fukumoto, “Cyclotron Versus Synchrotron for Proton Beam Therapy,” KEK Prepr., No. 95-122, Oct. 1995, pp. 533-536.
Goto et al., “Progress on the Sector Magnets for the Riken SRC,” American Institute of Physics, CP600, Cyclotrons and Their Applications 2001, Sixteenth International Conference, 2001, pp. 319-323.
Graffman et al., “Design Studies for a 200 MeV Proton Clinic for Radiotherapy,” AIP Conference Proceedings: Cyclotrons—1972, 1972, No. 9, pp. 603-615.
Graffman et al., Acta Radial. Therapy Phys. Biol. 1970, 9, 1 (1970).
Graffman, et. al. “Proton radiotherapy with the Uppsala cyclotron. Experience and plans” Strahlentherapie, 1985, 161(12):764-770.
Hede, “Research Groups Promoting Proton Therapy “Lite,”” Journal of the National Cancer Institute, Dec. 6, 2006, 98(23):1682-1684.
Heinz, “Superconducting Pulsed Magnetic Systems for High-Energy Synchrotrons,” Proceedings of the Fourth International Cryogenic Engineering Conference, May 24-26, 1972, pp. 55-63.
Hentschel et al., “Plans for the German National Neutron Therapy Centre with a Hospital-Based 70 MeV Proton Cyclotron at University Hospital Essen/Germany,” Cyclotrons and their Applications, Proceedings of the Fifteenth International Conference on Cyclotrons and their Applications, Caen, Franco, Jun. 14-19, 1998, pp. 21-23.
Hepburn et al., “Superconducting Cyclotron Neutron Source for Therapy,” International Journal of Radiation Oncology Biology Physics, vol. 3 complete, 1977, pp. 387-391.
Hirabayashi, “Development of Superconducting Magnets for Beam Lines and Accelerator at KEK,” IEEE Transaction on Magnetics, Jan. 1981, Mag-17(1):728-731.
Ishibashi and McInturff, “Winding Design Study of Superconducting 10 T Dipoles for a Synchrotron,” IEEE Transactions on Magnetics, May 1983, MAG-19(3):1364-1367.
Ishibashi and McInturff, “Stress Analysis of Superconducting 10T Magnets for Synchrotron,” Proceedings of the Ninth International Cryogenic Engineering Conference, May 11-14, 1982, pp. 513-516.
Jahnke et al., “First Superconducting Prototype Magnets for a Compact Synchrotron Radiation Source in Operation,” IEEE Transactions on Magnetics, Mar. 1988, 24(2):1230-1232.
Jones and Dershem, “Synchrotron Radiation from Proton in a 20 TEV, 10 TESLA Superconducting Super Collide,r” Proceedings of the 12th International Conference on High-Energy Accelerator, Aug. 11-16, 1983, pp. 138-140.
Jones and Mills, “The South African National Accelerator Centre: Particle Therapy and Isotope Production Programmes,” Radiation Physics and Chemistry, Apr.-Jun. 1998, 51(4-6):571-578.
Jones et al., “Status Report of the NAC Particle Therapy Programme,” Stralentherapie und Onkologie, vol. 175, Suppl. II, Jun. 1999, pp. 30-32.
Jones, “Progress with the 200 MeV Cyclotron Facility at the National Accelerator Centre,” Commission of the European Communities Radiation Protection Proceedings, Fifth Symposium on Neutron Dosimetry, Sep. 17-21, 1984, vol. II, pp. 989-998.
Jones, “Present Status and Future Trends of Heavy Particle Radiotherapy,” Cyclotrons and their Applications 1998, Proceedings of the Fifteenth International Conference on Cyclotrons and their Applications, Jun. 14-19, 1998, pp. 13-20.
Jongen et al., “Development of a Low-cost Compact Cyclotron System for Proton Therapy,” National Institute of Radiol. Sci, 1991, No. 81, pp. 189-200.
Jongen et al., “Progress report on the IBA-SHI small cyclotron for cancer therapy” Nuclear Instruments and Methods in Physics Research, Section B, vol. 79, issue 1-4, 1993, pp. 885-889.
Jongen et al., “The proton therapy system for the NPTC: Equipment Description and progress report,” Nuclear Instruments and methods in physics research, 1996, Section B, 113(1): 522-525.
Jongen et al., “The proton therapy system for MGH's NPTC: equipment description and progress report,” Bulletin du Cancer/Radiotherapie, Proceedings of the meeting of the European Heavy Particle Therapy Group, 1996, 83(Suppl. 1):219-222.
Kanai et al., “Three-dimensional Beam Scanning for Proton Therapy,” Nuclear Instruments and Methods in Physic Research, Sep. 1, 1983, The Netherlands, 214(23):491-496.
Karlin et al., “Medical Radiology” (Moscow), 1983, 28, 13.
Karlin et al., “The State and Prospects in the Development of the Medical Proton Tract on the Synchrocyclotron in Gatchina,” Med. Radiol., Moscow, 28(3):28-32 (Mar. 1983)(German with English Abstract on end of p. 32).
Kats and Druzhinin, “Comparison of Methods for Irradiation Prone Patients,” Atomic Energy, Feb. 2003, 94(2):120-123.
Kats and Onosovskii, “A Simple, Compact, Flat System for the Irradiation of a Lying Patient with a Proton Beam from Different Directions,” Instruments and Experimental Techniques, 1996, 39(1): 132-134.
Kats and Onosovskii, “A Planar Magnetooptical System for the Irradiation of a Lying Patient with a Proton Beam from Various Directions,” Instruments and Experimental Techniques, 1996, 39(1):127-131.
Khoroshkov et al.,“Moscow Hospital-Based Proton Therapy Facility Design,” Am. Journal Clinical Oncology: CCT, Apr. 1994, 17(2):109-114.
Kim and Blosser, “Optimized Magnet for a 250 MeV Proton Radiotherapy Cyclotron,” Cyclotrons and Their Applications 2001, May 2001, Sixteenth International Conference, pp. 345-347.
Kim and Yun, “A Light-Ion Superconducting Cyclotron System for Multi-Disciplinary Users,” Journal of the Korean Physical Society, Sep. 2003, 43(3):325-331.
Kim et al., “Construction of 8T Magnet Test Stand for Cyclotron Studies,” IEEE Transactions on Applied Superconductivity, Mar. 1993, 3(1):266-268.
Kim et al., “Design Study of a Superconducting Cyclotron for Heavy Ion Therapy,” Cyclotrons and Their Applications 2001, Sixteenth International Conference, May 13-17, 2001, pp. 324-326.
Kim et al., “Trim Coil System for the Riken Cyclotron Ring Cyclotron,” Proceedings of the 1997 Particle Accelerator Conference, IEEE, Dec. 1981, vol. 3, pp. 214-235 or 3422-3424, 1998.
Kim, “An Eight Tesla Superconducting Magnet for Cyclotron Studies,” Ph.D. Dissertation, Michigan State University, Department of Physics and Astronomy, 1994, 138 pages.
Kimstrand, “Beam Modelling for Treatment Planning of Scanned Proton Beams,” Digital Comprehensive Summaries of Uppsala dissertations from the Faculty of Medicine 330, Uppsala Universitet, 2008, 58 pages.
Kishida and Yano, “Beam Transport System for the RIKEN SSC (II),” Scientific Papers of the Institute of Physical and Chemical Research, Dec. 1981, 75(4):214-235.
Koehler et al., “Range Modulators for Protons and Heavy Ions,” Nuclear Instruments and Methods, 1975, vol. 131, pp. 437-440.
Koto and Tsujii, “Future of Particle Therapy,” Japanese Journal of Cancer Clinics, 2001, 47(1):95-98 [Lang.: Japanese], English abstract (http://sciencelinks.jp/j-east/article/200206/000020020601A0511453.php).
Kraft et al., “Hadrontherapy in Oncology,” U. Amaldi and Larrsson, editors Elsevier Science, 1994, 390 pages.
Krevet et al., “Design of a Strongly Curved Superconducting Bending Magnet for a Compact Synchrotron Light Source,” Advances in Cryogenic Engineering, 1988, vol. 33, pp. 25-32.
Laisne et al., “The Orsay 200 MeV Synchrocyclotron,” IEEE Transactions on Nuclear Science, Apr. 1979, NS-26(2):1919-1922.
Larsson et al., Nature,1958, 182:1222.
Larsson, “Biomedical Program for the Converted 200-MeV Synchrocyclotron at the Gustaf Werner Institute,” Radiation Research, 1985, 104:S310-S318.
Lawrence et al., “Heavy particles in acromegaly and Cushing's Disease,” in Endocrine and Norendocrine Hormone Producing Tumors (Year Book Medical Chicago, 1973, pp. 29-61.
Lawrence et al., “Successful Treatment of Acromegaly: Metabolic and Clinical Studies in 145 Patients,” The Journal of Clinical Endrocrinology and Metabolism, Aug. 1970, 31(2), 21 pages.
Lawrence et al., “Treatment of Pituitary Tumors,” (Excerpta medica, Amsterdam/American Elsevier, New York, 1973, pp. 253-262.
Lawrence, Cancer, 1957, 10:795.
Lecroy et al., “Viewing Probe for High Voltage Pulses,” Review of Scientific Instruments USA, Dec. 1960, 31(12):1354.
Lin et al., “Principles and 10 Year Experience of the Beam Monitor System at the PSI Scanned Proton Therapy Facility”, Center for Proton Radiation Therapy, Paul Scherrer Institute, CH-5232, Villigen PSI, Switzerland, 2007, 21 pages.
Linfoot et al., “Acromegaly,” in Hormonal Proteins and Peptides, edited by C.H. Li, 1975, pp. 191-246.
Literature Author and Keyword Search, Feb. 14, 2005, 44 pages.
Literature Keyword Search, Jan. 24, 2005, 98 pages.
Literature Search and Keyword Search for Synchrocyclotron, Jan. 25, 2005, 68 pages.
Literature Search by Company Name/Component Source, Jan. 24, 2005, 111 pages.
Literature Search, Jan. 26, 2005, 37 pages.
Livingston et al., “A capillary ion source for the cyclotron,” Review Science Instruments, Feb. 1939, 10:63.
Mandrillon, “High Energy Medical Accelerators,” EPAC 90, 2nd European Particle Accelerator Conference, Jun. 12-16, 1990, 2:54-58.
Marchand et al., “IBA Proton Pencil Beam Scanning: an Innovative Solution for Cancer Treatment,” Proceedings of EPAC 2000, Vienna, Austria, 3 pages.
Marti et al., “High Intensity Operation of a Superconducting Cyclotron,” Proceedings of the 14the International Conference, Cyclotrons and Their Applications, Oct. 1995, pp. 45-48 (Oct. 1995).
Martin, “Operational Experience with Superconducting Synchrotron Magnets” Proceedings of the 1987 IEEE Particle Accelerator Conference, Mar. 16-19, 1987, vol. 3 of 3:1379-1382.
Meote et al., “ETOILE Hadrontherapy Project, Review of Design Studies” Proceedings of EPAC 2002, 2002, pp. 2745-2747.
Miyamoto et al., “Development of the Proton Therapy System,” The Hitachi Hyoron, 79(10):775-779 (1997) [Lang: Japanese], English abstract (http://www.hitachi.com/rev/1998/revfeb98/rev4706.htm).
Montelius et al., “The Narrow Proton Beam Therapy Unit at the Svedberg Laboratory in Uppsala,” ACTA Oncologica, 1991, 30:739-745.
Moser et al., “Nonlinear Beam Optics with Real Fields in Compact Storage Rings,” Nuclear Instruments & Methods in Physics Research/Section B, B30, Feb. 1988, No. 1, pp. 105-109.
Moyers et al., “A Continuously Variable Thickness Scatterer for Proton Beams Using Self-compensating Dual Linear Wedges” Lorna Linda University Medical Center, Dept. of Radiation Medicine, Lorna Linda, CA, Nov. 2, 1992, 21 pages.
National Cancer Institute Funding (Senate-Sep. 21, 1992) (www.thomas.loc.gov/cgi-bin/query/z?r102:S21SE2-712 (2 pages).
Nicholson, “Applications of Proton Beam Therapy,” Journal of the American Society of Radiologic Technologists, May/Jun. 1996, 67(5): 439-441.
Nolen et al., “The Integrated Cryogenic—Superconducting Beam Transport System Planned for MSU,” Proceedings of the 12th International Conference on High-Energy Accelerators, Aug. 1983, pp. 549-551.
Norimine et al., “A Design of a Rotating Gantry with Easy Steering for Proton Therapy,” Proceedings of EPAC 2002, 2002, pp. 2751-2753.
Ogino, Takashi, “Heavy Charged Particle Radiotherapy-Proton Beam”, Division of Radiation Oncology, National Cancer Hospital East, Kashiwa, Japan, Dec. 2003, 7 pages.
Okumura et al., “Overview and Future Prospect of Proton Radiotherapy,” Japanese Journal of Cancer Clinics, 1997, 43(2):209-214 [Lang.: Japanese].
Okumura et al., “Proton Radiotherapy” Japanese Journal of Cancer and Chemotherapy, 1993, 10.20(14):2149-2155[Lang.: Japanese].
Outstanding from Search Reports, “Accelerator of Polarized Portons at Fermilab,” 2005, 20 pages.
Paganetti et al., “Proton Beam Radiotherapy—The State of the Art,” Springer Verlag, Heidelberg, ISBN 3-540-00321-5, Oct. 2005,36 pages.
Palmer and Tollestrup, “Superconducting Magnet Technology for Accelerators,” Annual Review of Nuclear and Particle Science, 1984, vol. 34, pp. 247-284.
Patent Assignee and Keyword Searches for Synchrocyclotron, Jan. 25, 2005, 78 pages.
Pavlovic, “Beam-optics study of the gantry beam delivery system for light-ion cancer therapy,” Nuclear Instruments and Methods in Physics Research, Section A, Nov. 1997, 399(2):439-454(16).
Pedroni and Enge, “Beam optics design of compact gantry for proton therapy” Medical & Biological Engineering & Computing, May 1995, 33(3):271-277.
Pedroni and Jermann, “SGSMP: Bulletin Mar. 2002 Proscan Project, Progress Report on the PROSCAN Project of PSI” [online] retrieved from www.sgsmp.ch/protA23.htm, Mar. 2002, 5 pages.
Pedroni et al., “A Novel Gantry for Proton Therapy at the Paul Scherrer Institute,” Cycloctrons and Their Applications 2001: Sixteenth International Conference. AIP Conference Proceedings, 2001, 600:13-17.
Pedroni et al., “The 200-MeV proton therapy project at the Paul Scherrer Institute: Conceptual design and practical realization,” Medical Physics, Jan. 1995, 22(1):37-53.
Pedroni, “Accelerators for Charged Particle Therapy: Performance Criteria from the User Point of View,” Cyclotrons and their Applications, Proceedings of the 13th International Conference, Jul. 6-10, 1992, pp. 226-233.
Pedroni, “Latest Developments in Proton Therapy” Proceedings of EPAC 2000, pp. 240-244, 2000.
Pedroni, “Status of Proton Therapy: results and future trends,” Paul Scherrer Institute, Division of Radiation Medicine, 1994, 5 pages.
Peggs et al., “A Survey of Hadron Therapy Accelerator Technologies,” Particle Accelerator Conference, Jun. 25-29, 2007, 7 pages.
Potts et al., “MPWP6-Therapy III: Treatment Aids and Techniques” Medical Physics, Sep./Oct. 1988, 15(5):798.
Pourrahimi et al., “Powder Metallurgy Processed Nb3Sn(Ta) Wire for High Field NMR magnets,” IEEE Transactions on Applied Superconductivity, Jun. 1995, 5(2):1603-1606.
Prieels et al., “The IBA State-of-the-Art Proton Therapy System, Performances and Recent Results,” Application of Accelerators in Research and industry—Sixteenth Int'l. Conf., American Institute of Physics, Nov. 1-5, 2000, 576:857-860.
Rabin et al., “Compact Designs for Comprehensive Proton Beam Clinical Facilities,” Nuclear Instruments & Methods in Physics Research, Apr. 1989, Section B, vol. 40-41, Part II, pp. 1335-1339.
Research & Development Magazine, “Proton Therapy Center Nearing Completion,” Aug. 1999, 41(9):2 pages, (www.redmag.com).
Resmini, “Design Characteristics of the K=800 Superconducting Cyclotron at M.S.U.,” Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, IEEE Transaction on Nuclear Science, vol. NS-26, No. 2, Apr. 1979, 8 pages.
RetroSearch “Berkeley 88-Inch Cyclotron ‘RF’ or ‘Frequency Control’,” Jan. 21, 2005, 36 pages.
RetroSearch “Berkeley 88-Inch Cyclotron,” Jan. 24, 2005, 170 pages.
RetroSearch “Bernard Gottschalk, Cyclotron, Beams, Compensated Upstream Modulator, Compensated Scatter,” Jan. 21, 2005, 20 pages.
RetroSearch “Cyclotron with ‘RF’ or ‘Frequency Control’,” Jan. 21, 2005, 49 pages.
RetroSearch Gottschalk, Bernard, Harvard Cyclotron Wheel, Jan. 21, 2005, 20 pages.
RetroSearch “Loma Linda University Beam Compensation,” Jan. 21, 2005, 60 pages.
RetroSearch “Loma Linda University, Beam Compensation Foil Wedge,” Jan. 21, 2005, 15 pages.
Revised Patent Keyword Search, Jan. 25, 2005, 88 pages.
Rifuggiato et, al., “Status Report of the LNS Superconducting Cyclotron” Nukleonika, 2003, 48: S131-S134, Supplement 2.
Rode, “Tevatron Cryogenic System,” Proceedings of the 12th International Conference on High-energy Accelerators, Fermilab, Aug. 11-16, 1983, pp. 529-535.
Salzburger et al., “Superconducting Synchrotron Magnets Supraleitende Synchrotronmagnete,” Siemens A.G., Erlangen (West Germany). Abteilung Technische Physik, Report No. BMFT-FB-T-75-25, Oct. 1975, p. 147, Journal Announcement: GRAI7619; STAR1415, Subm-Sponsored by Bundesmin. Fuer Forsch. U. Technol. In German; English Summary.
Schillo et al,. “Compact Superconducting 250 MeV Proton Cyclotron for the PSI Proscan Proton Therapy Project,” Cyclotrons and Their Applications 2001, Sixteenth International Conference, 2001, pp. 37-39.
Schneider et al., “Nevis Synchrocyclotron Conversion Program—RF System,” IEEE Transactions on Nuclear Science USA, Jun. 1969, ns 16(3): 430-433.
Schneider et al., “Superconducting Cyclotrons,” IEEE Transactions on Magnetics, vol. MAG-11, No. 2, Mar. 1975, New York, pp. 443-446.
Schreuder et al., “The Non-orthogonal Fixed Beam Arrangement for the Second Proton Therapy Facility at the National Accelerator Centre,” Application of Accelerators in Research and Industry, American Institute of Physics, Proceedings of the Fifteenth International Conference, Nov. 1998, Part Two, pp. 963-966.
Schreuder, “Recent Developments in Superconducting Cyclotrons,” Proceedings of the 1995 Particle Accelerator Conference, May 1-5, 1995, vol. 1, pp. 317-321.
Schubert and Blosser, “Conceptual Design of a High Field Ultra-Compact Cyclotron for Nuclear Physics Research,” Proceedings of the 1997 Particle Accelerator Conference, May 12-16, 1997, vol. 1, 3 pp. 1060-1062.
Schubert, “Extending the Feasibility Boundary of the Isochronous Cyclotron,” Dissertation submitted to Michigan State University, 1997, Abstract http://adsabs.harvard.edu/abs/1998PhDT . . . 147S.
Shelaev et al., “Design Features of a Model Superconducting Synchrotron of JINR,” Proceedings of the 12th International Conference on High-energy Accelerators, Aug. 11-16, 1983, pp. 416-418.
Shintomi et. Al, “Technology and Materials for the Superconducting Super Collider (SSC) Project,” [Lang.: Japanese], The Iron and Steel Institute of Japan 00211575, 78(8): 1305-1313, 1992, http://ci.nii.ac.jp/naid/110001493249/en/.
Sisterson, “World Wide Proton Therapy Experience in 1997,” The American Insitute of Physics, Applications of Accelerators in Research and Industry, Proceedings of the Fifteenth International Conference, Part Two, Nov. 1998, pp. 959-962.
Sisterson, “Clinical use of proton and ion beams from a world-wide perspective,” Nuclear Instruments and Methods in Physics Research, Section B, 1989, 40-41:1350-1353.
Slater et al., “Developing a Clinical Proton Accelerator Facility: Consortium-Assisted Technology Transfer,” Conference Record of the 1991 IEEE Particle Accelerator Conference: Accelerator Science and Technology, vol. 1, May 6-9, 1991, pp. 532-536.
Slater et al., “Development of a Hospital-Based Proton Beam Treatment Center,” International Journal of Radiation Oncology Biology Physics, Apr. 1988, 14(4):761-775.
Smith et al., “The Northeast Proton Therapy Center at Massachusetts General Hospital” Journal of Brachytherapy International, Jan. 1997, pp. 137-139.
Snyder and Marti, “Central region design studies for a proposed 250 MeV proton cyclotron,” Nuclear Instruments and Methods in Physics Research, Section A, 1995, vol. 355, pp. 618-623.
Soga, “Progress of Particle Therapy in Japan,” Application of Accelerators in Research and Industry, American Institute of Physics, Sixteenth International Conference, Nov. 2000, pp. 869-872.
Spiller et al., “The GSI Synchrotron Facility Proposal for Acceleration of High Intensity Ion and Proton Beams” Proceedings of the 2003 Particle Accelerator Conference, May 12-16, 2003, vol. 1, pp. 589-591.
Stanford et al., “Method of Temperature Control in Microwave Ferroelectric Measurements,” Sperry Microwave Electronics Company, Clearwater, Florida, Sep. 19, 1960, 1 page.
Tadashi et al., “Large superconducting super collider (SSC) in the planning and materials technology,”78(8):1305-1313, The Iron and Steel Institute of Japan 00211575, Aug. 1992.
Takada, “Conceptual Design of a Proton Rotating Gantry for Cancer Therapy,” Japanese Journal of Medical Physics, 1995, 15(4):270-284.
Takayama et al., “Compact Cyclotron for Proton Therapy,” Proceedings of the 8th Symposium on Accelerator Science and Technology, Japan, Nov. 25-27, 1991, pp. 380-382.
Teng, “The Fermilab Tevatron,” Coral Gables 1981, Proceedings, Gauge Theories, Massive Neutrinos, and Proton Decay, 1981, pp. 43-62.
The Journal of Practical Pharmacy, 1995, 46(1):97-103 [Japanese].
Tilly, et al., “Development and verification of the pulsed scanned proton beam at The Svedberg Laboratory in Uppsala”, Physics in Medicine and Biology, Phys. Med. Biol. 52, pp. 2741-2454, 2007.
Tobias et al., Cancer Research,1958, 18, 121 (1958).
Tom, “The Use of Compact Cyclotrons for Producing Fast Neutrons for Therapy in a Rotatable Isocentric Gantry,” IEEE Transaction on Nuclear Science, Apr. 1979, 26(2):2294-2298.
Toyoda, “Proton Therapy System”, Sumitomo Heavy Industries, Ltd., 2000, 5 pages.
Trinks et. al., “The Tritron: A Superconducting Separated-Orbit Cyclotron,” Nuclear Instruments and Methods in Physics Research, Section A, 1986, vol. 244, pp. 273-282.
Tsuji, “The Future and Progress of Proton Beam Radiotherapy,” Journal of Japanese Society for Therapeutic Radiology and Oncology, 1994, 6(2):63-76.
UC Davis School of Medicine, “Unlikely Partners Turn Military Defense into Cancer Offense”, Current Issue Summer 2008, Sacramento, California, pp. 1-2.
Umegaki et al., “Development of an Advanced Proton Beam Therapy System for Cancer Treatment” Hitachi Hyoron, 2003, 85(9):605-608 [Lang.: Japanese], English abstract, http://www.hitachi.com/ICSFiles/afieldfile/2004/06/01/r2003—04—104.pdf or http://wwvv.hitachi.com/rev/archive/2003/2005649—12606.html (full text) [Hitachi, 52(4), Dec. 2003].
Umezawa et al., “Beam Commissioning of the new Proton Therapy System for University of Tsukuba,” Proceedings of the 2001 Particle Accelerator Conference, vol. 1, Jun. 18-22, 2001, pp. 648-650.
van Steenbergen, “Superconducting Synchroton Development at BNL,” Proceedings of the 8th International Conference on High-Energy Accelerators CERN 1971, 1971, pp. 196-198.
van Steenbergen, “The CMS, a Cold Magnet Synchrotron to Upgrade the Proton Energy Range of the BNL Facility,” IEEE Transactions on Nuclear Science, Jun. 1971, 18(3):694-698.
Vandeplassche et al., “235 MeV Cyclotron for MGH's Northeast Proton Therapy Center (NPTC): Present Status,” EPAC 96, Fifth European Partical Accelerator Conference, vol. 3, Jun. 10-14, 1996, pp. 2650-2652.
Vorobiev et al., “Concepts of a Compact Achromatic Proton Gantry with a Wide Scanning Field”, Nuclear Instruments and Methods in Physics Research, Section A., 1998, 406(2):307-310.
Vrenken et al., “A Design of a Compact Gantry for Proton Therapy with 2D-Scanning,” Nuclear Instruments and Methods in Physics Research, Section A, 1999, 426(2):618-624.
Wikipedia, “Cyclotron” http://en.wikipedia.org/wiki/Cyclotron (originally visited Oct. 6, 2005, revisited Jan. 28, 2009), 7pages.
Wikipedia, “Synchrotron” http://en.wikipedia.org/wiki/Synchrotron (originally visited Oct. 6, 2005, revisited Jan. 28, 2009), 7 pages.
Worldwide Patent Assignee Search, Jan. 24, 2005, 224 pages.
Worldwide Patent Keyword Search, Jan. 24, 2005, 94 pages.
Wu, “Conceptual Design and Orbit Dynamics in a 250 MeV Superconducting Synchrocyclotron,” Ph.D. Dissertation, Michigan State University, Department of Physics and Astronomy, 1990, 172 pages.
York et al., “Present Status and Future Possibilities at NSCL-MSU,” EPAC 94, Fourth European Particle Accelerator Conference, pp. 554-556, Jun. 1994.
York et al., “The NSCL Coupled Cyclotron Project—Overview and Status,”Proceedings of the Fifteenth International Conference on Cyclotrons and their Applications, Jun. 1998, pp. 687-691.
Yudelev et al., “Hospital Based Superconducting Cyclotron for Neutron Therapy: Medical Physics Perspective,” Cyclotrons and their applications 2001, 16th International Conference. American Institute of Physics Conference Proceedings, vol. 600, May 13-17, 2001, pp. 40-43.
Zherbin et al., “Proton Beam Therapy at the Leningrad Synchrocyclotron (Clinicomethodological Aspects and Therapeutic Results)”, Aug. 1987, 32(8):17-22, (German with English abstract on pp. 21-22).
International Search Report and Written Opinion from PCT application No. PCT/US2013/062119 mailed on Nov. 26, 2013 (9 pages).
International Preliminary Report on Patentability from PCT application No. PCT/US2013/062119 mailed on Apr. 9, 2015 (7 pages).

Related Publications (1)

	Number	Date	Country
	20140091734 A1	Apr 2014	US

Provisional Applications (1)

	Number	Date	Country
	61707645	Sep 2012	US

Control system for a particle accelerator

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

Field of Search

CPC

International Classifications

Term Extension

Abstract